CA2697358A1 - Balloon mitral spacer - Google Patents
Balloon mitral spacer Download PDFInfo
- Publication number
- CA2697358A1 CA2697358A1 CA2697358A CA2697358A CA2697358A1 CA 2697358 A1 CA2697358 A1 CA 2697358A1 CA 2697358 A CA2697358 A CA 2697358A CA 2697358 A CA2697358 A CA 2697358A CA 2697358 A1 CA2697358 A1 CA 2697358A1
- Authority
- CA
- Canada
- Prior art keywords
- shaft
- expandable member
- heart valve
- valve implant
- valve body
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/24—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
- A61F2/2442—Annuloplasty rings or inserts for correcting the valve shape; Implants for improving the function of a native heart valve
- A61F2/2445—Annuloplasty rings in direct contact with the valve annulus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/24—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
- A61F2/2442—Annuloplasty rings or inserts for correcting the valve shape; Implants for improving the function of a native heart valve
- A61F2/246—Devices for obstructing a leak through a native valve in a closed condition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/24—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
- A61F2/2427—Devices for manipulating or deploying heart valves during implantation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/00234—Surgical instruments, devices or methods, e.g. tourniquets for minimally invasive surgery
- A61B2017/00238—Type of minimally invasive operation
- A61B2017/00243—Type of minimally invasive operation cardiac
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0003—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having an inflatable pocket filled with fluid, e.g. liquid or gas
Abstract
A heart valve implant according to one embodiment may include a shaft and an anchor disposed on one end of the shaft, the anchor configured to engage tissue. The heart valve implant may further include an expandable member disposed over at least part of the shaft, the expandable member comprising a resiliently deformable internal layer and a resiliently deformable external layer disposed over the internal layer, the expandable member defining a chamber and being configured to receive an inflation medium in the chamber to expand the expandable member, the expandable member further configured to deform upon contact with at least a portion of at least one leaflet of a heart valve to at least partially conform to the shape of the leaflet.
Description
BALLOON MITRAL SPACER
CROSS-REFERENCE TO RELATED APPLICATION
The subject application is a continuation-in-part of co-pending U.S. Patent Application Serial No. 11/258,828, entitled "Heart Valve Implant" filed on October 26, 2005, which is hereby incorporated by reference.
FIELD
The present disclosure relates to the repair and/or correction of dysfunctional heart valves, and more particularly pertains to heart valve implants and systems and methods for delivery and implementation of the same.
BACKGROUND
A human heart has four chambers, the left and right atrium and the left and right ventricles. The chambers of the heart alternately expand and contract to pump blood through the vessels of the body. The cycle of the heart includes the simultaneous contraction of the left and right atria, passing blood from the atria to the left and right ventricles.
The left and right ventricles then simultaneously contract forcing blood from the heart and through the vessels of the body. In addition to the four chambers, the heart also includes a check valve at the upstream end of each chamber to ensure that blood flows in the correct direction through the body as the heart chambers expand and contract. These valves may become damaged, or otherwise fail to function properly, resulting in their inability to properly close when the downstream chamber contracts. Failure of the valves to properly close may allow blood to flow backward through the valve resulting in decreased blood flow and lower blood pressure.
Mitral regurgitation is a common variety of heart valve dysfunction or insufficiency.
Mitral regurgitation occurs when the mitral valve separating the left coronary atrium and the left ventricle fails to properly close. As a result, upon contraction of the left ventricle blood may leak or flow from the left ventricle back into the left atrium, rather than being forced through the aorta. Any disorder that weakens or damages the mitral valve can prevent it from closing properly, thereby causing leakage or regurgitation. Mitral regurgitation is considered to be chronic when the condition persists rather than occurring for only a short period of time.
Regardless of the cause, mitral regurgitation may result in a decrease in blood flow through the body (cardiac output). Correction of mitral regurgitation typically requires surgical intervention. Surgical valve repair or replacement may be carried out as an open heart procedure. The repair or replacement surgery may last in the range of about three to five hours, and may be carried out with the patient under general anesthesia. The nature of the surgical procedure requires the patient to be placed on a heart-lung machine. Because of the severity/complexity/danger associated with open heart surgical procedures, corrective surgery for mitral regurgitation is typically not recommended until the patient's ejection fraction drops below 60% and/or the left ventricle is larger than 45 mm at rest.
BRIEF DESCRIPTION OF THE DRAWINGS
Features and advantage of the claimed subject matter will be apparent from the following description of embodiments consistent therewith, which description should be considered in conjunction with the accompanying drawings, wherein:
FIG. 1 is a perspective view of an embodiment of a mitral valve implant consistent with the present disclosure;
FIG. 2 depicts an embodiment mitral valve implant consistent with the present disclosure implanted within a heart in an open position;
FIG. 3 depicts an embodiment of a mitral valve implant consistent with the present disclosure implanted within a heart in a closed position;
FIG. 4 depicts another embodiment of a mitral valve implant consistent with the present disclosure;
FIG. 5 depicts the mitral valve implant of FIG. 4 implanted within a heart in an open position;
FIG. 6 depicts the mitral valve implant of FIG. 4 implanted within a heart in a closed position;
FIG. 7 shows another embodiment of a mitral valve implant consistent with the present disclosure;
FIG. 8 shows an embodiment of a mitral valve implant including a barb anchor portion consistent with the present disclosure;
FIG. 9 depicts another embodiment of a translating mitral valve implant consistent with the present disclosure;
FIG. 10 schematically shows and embodiment of a percutaneous mitral valve implant delivery system consistent with the present disclosure;
FIG. 11 is a cross-sectional view of an embodiment of an inflatable valve body consistent with the present disclosure;
CROSS-REFERENCE TO RELATED APPLICATION
The subject application is a continuation-in-part of co-pending U.S. Patent Application Serial No. 11/258,828, entitled "Heart Valve Implant" filed on October 26, 2005, which is hereby incorporated by reference.
FIELD
The present disclosure relates to the repair and/or correction of dysfunctional heart valves, and more particularly pertains to heart valve implants and systems and methods for delivery and implementation of the same.
BACKGROUND
A human heart has four chambers, the left and right atrium and the left and right ventricles. The chambers of the heart alternately expand and contract to pump blood through the vessels of the body. The cycle of the heart includes the simultaneous contraction of the left and right atria, passing blood from the atria to the left and right ventricles.
The left and right ventricles then simultaneously contract forcing blood from the heart and through the vessels of the body. In addition to the four chambers, the heart also includes a check valve at the upstream end of each chamber to ensure that blood flows in the correct direction through the body as the heart chambers expand and contract. These valves may become damaged, or otherwise fail to function properly, resulting in their inability to properly close when the downstream chamber contracts. Failure of the valves to properly close may allow blood to flow backward through the valve resulting in decreased blood flow and lower blood pressure.
Mitral regurgitation is a common variety of heart valve dysfunction or insufficiency.
Mitral regurgitation occurs when the mitral valve separating the left coronary atrium and the left ventricle fails to properly close. As a result, upon contraction of the left ventricle blood may leak or flow from the left ventricle back into the left atrium, rather than being forced through the aorta. Any disorder that weakens or damages the mitral valve can prevent it from closing properly, thereby causing leakage or regurgitation. Mitral regurgitation is considered to be chronic when the condition persists rather than occurring for only a short period of time.
Regardless of the cause, mitral regurgitation may result in a decrease in blood flow through the body (cardiac output). Correction of mitral regurgitation typically requires surgical intervention. Surgical valve repair or replacement may be carried out as an open heart procedure. The repair or replacement surgery may last in the range of about three to five hours, and may be carried out with the patient under general anesthesia. The nature of the surgical procedure requires the patient to be placed on a heart-lung machine. Because of the severity/complexity/danger associated with open heart surgical procedures, corrective surgery for mitral regurgitation is typically not recommended until the patient's ejection fraction drops below 60% and/or the left ventricle is larger than 45 mm at rest.
BRIEF DESCRIPTION OF THE DRAWINGS
Features and advantage of the claimed subject matter will be apparent from the following description of embodiments consistent therewith, which description should be considered in conjunction with the accompanying drawings, wherein:
FIG. 1 is a perspective view of an embodiment of a mitral valve implant consistent with the present disclosure;
FIG. 2 depicts an embodiment mitral valve implant consistent with the present disclosure implanted within a heart in an open position;
FIG. 3 depicts an embodiment of a mitral valve implant consistent with the present disclosure implanted within a heart in a closed position;
FIG. 4 depicts another embodiment of a mitral valve implant consistent with the present disclosure;
FIG. 5 depicts the mitral valve implant of FIG. 4 implanted within a heart in an open position;
FIG. 6 depicts the mitral valve implant of FIG. 4 implanted within a heart in a closed position;
FIG. 7 shows another embodiment of a mitral valve implant consistent with the present disclosure;
FIG. 8 shows an embodiment of a mitral valve implant including a barb anchor portion consistent with the present disclosure;
FIG. 9 depicts another embodiment of a translating mitral valve implant consistent with the present disclosure;
FIG. 10 schematically shows and embodiment of a percutaneous mitral valve implant delivery system consistent with the present disclosure;
FIG. 11 is a cross-sectional view of an embodiment of an inflatable valve body consistent with the present disclosure;
FIG. 12 is a cross-sectional view of an embodiment of an expandable valve body consistent with the present disclosure;
FIG. 13 is a cross-sectional view of an embodiment of an expandable valve body consistent with the present disclosure including a recoverably deformable rib;
FIG. 14 is a cross-sectional view of another embodiment of an expandable valve body consistent with the present disclosure including recoverably deformable stringers;
FIG. 15 is perspective view of a valve body of yet another embodiment of a mitral valve implant consistent with the present disclosure;
FIG. 16A is a perspective view of an additional embodiment of a mitral valve implant in accordance with the present disclosure;
FIG. 16B is a cross-sectional view of the mitral valve implant shown in FIG.
16A;
FIG. 17A depicts the mitral valve implant of FIGS. 16A-B shown in an at rest position;
FIG. 17B depicts the mitral valve implant of FIGS. 16A-B shown in an expanded position;
FIG. 18 is a perspective view of yet another embodiment of a mitral valve implant in accordance with the present disclosure;
FIG. 19 is a perspective view of another embodiment of a mitral valve implant in accordance with the present disclosure;
FIG. 20 is a perspective view of an embodiment of a mitral valve implant in accordance with the present disclosure;
FIG. 21 is a perspective view of yet another embodiment of a mitral valve implant in accordance with the present disclosure;
FIG. 13 is a cross-sectional view of an embodiment of an expandable valve body consistent with the present disclosure including a recoverably deformable rib;
FIG. 14 is a cross-sectional view of another embodiment of an expandable valve body consistent with the present disclosure including recoverably deformable stringers;
FIG. 15 is perspective view of a valve body of yet another embodiment of a mitral valve implant consistent with the present disclosure;
FIG. 16A is a perspective view of an additional embodiment of a mitral valve implant in accordance with the present disclosure;
FIG. 16B is a cross-sectional view of the mitral valve implant shown in FIG.
16A;
FIG. 17A depicts the mitral valve implant of FIGS. 16A-B shown in an at rest position;
FIG. 17B depicts the mitral valve implant of FIGS. 16A-B shown in an expanded position;
FIG. 18 is a perspective view of yet another embodiment of a mitral valve implant in accordance with the present disclosure;
FIG. 19 is a perspective view of another embodiment of a mitral valve implant in accordance with the present disclosure;
FIG. 20 is a perspective view of an embodiment of a mitral valve implant in accordance with the present disclosure;
FIG. 21 is a perspective view of yet another embodiment of a mitral valve implant in accordance with the present disclosure;
FIG. 22A is a perspective view of an additional embodiment of a mitral valve implant in accordance with the present disclosure;
FIG. 22B depicts the mitral valve implant of FIG. 22A shown in an expanded position;
and FIG. 23 is a perspective view of yet another embodiment of a mitral valve implant having a detachable valve body.
DESCRIPTION
The present disclosure relates to a heart valve implant. A heart valve implant herein may suitably be used in connection with the treatment and/or correction of a dysfunctional or inoperative heart valve. One suitable implementation for a heart valve implant consistent with the present disclosure is the treatment of mitral valve regurgitation. For the ease of explanation, the heart valve implant herein is described in terms of a mitral valve implant, such as may be used in treating mitral valve regurgitation. However, a heart valve implant consistent with the present disclosure may be employed for treating and/or correcting other dysfunctional or inoperative heart valves. The present disclosure should not, therefore, be construed as being limited to use as a mitral valve implant.
Generally, a heart valve implant consistent with the present disclosure may interact with at least a portion of an existing heart valve to prevent and/or reduce regurgitation. For example, at least a portion of one or more cusps of the heart valve may interact with, engage, and/or seal against at least a portion of the heart valve implant when the heart valve is in a closed condition.
The interaction, engagement and/or sealing between at least a portion of at least one cusp and at least a portion of the heart valve implant may reduce and/or eliminate regurgitation in a heart valve, for example, providing insufficient sealing, including only a single cusp, e.g., following removal of a diseased and/or damaged cusp, and/or having a ruptured cordae. A
heart valve implant consistent with the present disclosure may be used in connection with various additional and/or alternative defects and/or deficiencies.
Referring to FIG. 1, a perspective view of an embodiment of a mitral valve implant 10 is depicted. In general, the mitral valve implant 10 may be capable of increasing the sealing and/or closure of the passage between the left ventricle and the left atrium during contraction of the left ventricle relative to damaged and/or leaking native valve. Accordingly, in some embodiments the mitral valve implant 10 may be capable of operating in combination with a partially operable and/or damaged mitral valve. That is, the mitral valve implant may interact and/or cooperate with at least a portion of the native mitral valve to reduce and/or eliminate excessive regurgitation. As shown, mitral valve implant may generally include a valve body portion 12 which may be coupled to a shaft 14. The shaft 14 may be coupled to an anchor portion 16.
The valve body portion 12 of the mitral valve implant 10 shown in FIG. 1 may have a generally tapered shape, including a sidewall 17 tapering outwardly from a narrow portion 18 adjacent to one end of the valve body 12 to an enlarged portion 20 adjacent to the other end of the valve body 12. The taper of the sidewall 17 may have a flared or belled shape, providing an at least partially concave geometry, as depicted in FIG. 1. In various other embodiments the valve body may include a sidewall having a generally uniform taper, providing a straight profile.
In still other embodiments, the sidewall of the valve body may exhibit a convex taper, producing an at least somewhat bulging tapered profile.
The enlarged portion 20 of the valve body 12 may have an arcuate profile around the circumference 22 of the proximal region of the enlarged portion 20. The bottom 24 of the enlarged portion 20 may be provided having a flat and/or arcuate shape.
Furthermore, the bottom 24 of the proximal region may include convex and/or concave contours.
According to an embodiment, the valve body 12 may be slidably coupled to the shaft 14.
The valve body 12 may include an opening 26 extending from the bottom 24 of the enlarged portion 20, through the valve body 12, and to the narrow portion 18. In one such embodiment, the opening 26 may extend generally axially through the valve body 12. The opening 26 may be sized to slidably receive at least a portion of the shaft 14 therethrough. The shaft 14 may include one or more stops 28, 30. The stops 28, 30 may be sized and/or shaped to control and/or restrict translation of the valve body 12 along the shaft 14 beyond the respective stops 28, 30. In this manner, in the illustrated embodiment, translation of the valve body 12 along the shaft 14 may be restricted to the expanse of the shaft 14 between the stops 28, 30.
One or more of the stops 28, 30 may be integrally formed with the shaft 14.
Furthermore, one or more of the stops 28, 30 may be provided as a separate member coupled to and/or formed on the shaft 14. In an embodiment in which one or more of the stops 28, 30 are integrally formed with the shaft 14, the valve body 12 may be slidably coupled to the shaft 14 by pressing the valve body 12 over at least one of the stops 28, 30, which may at least partially elastically deform the opening 26 to permit passage of at least one of the stops 28, 30.
Once the one or more of the stops 28, 30 have been pressed through the opening 26, the opening 26 may at least partially elastically recover, thereby resisting passage of the one or more stops 28, 30 back through the opening 26. Various other arrangements may be employed for providing stops on the shaft and/or for controlling and/or limiting translation of the valve body along the shaft.
The anchor portion 16 may include a helical member 32 coupled to the shaft 14.
As shown, the helical member 32 may be loosely wound such that adjacent turns of the helical member 32 do not contact one another, for example resembling a corkscrew-type configuration.
The anchor portion 16 may be engaged with tissue by rotating the anchor portion 16 about the axis of the helical member 32, thereby advancing the anchor portion 16 into tissue. Consistent with such an embodiment, the anchor portion 16 may resist pulling out from the tissue. The anchor portion 16 may be provided as an extension of the shaft 14 wound in a helical configuration. Consistent with related embodiments, the anchor portion 16 may be formed as a separate feature and may be coupled to the shaft 14, e.g., using mechanical fasteners, welding, adhesive, etc.
According to various alternative embodiments, the anchor portion may include various configurations capable of being coupled to and/or otherwise attached to native coronary tissue.
For example, the anchor portion may include one or more prongs adapted to pierce coronary tissue and to alone, or in conjunction with other features, resist removal of the anchor portion from tissue. For example, the anchor portion may include a plurality of prongs which may engage native coronary tissue. According to various other embodiments, the anchor portion may include features that may facilitate attachment by suturing. Exemplary features to facilitate suturing may include rings or openings, suture penetrable tabs, etc. Various other anchor portions that may allow attachment or coupling to native coronary tissue may also suitably be employed in connection with the present disclosure.
Turning to FIGS. 2 and 3, the mitral valve implant 10 is shown implanted within a heart 102. The mitral valve implant 10 may be disposed at least partially within the left ventricle 104 of the heart 102. As shown, the anchor portion 16 may be engaged with native coronary tissue within and/or adjacent to the left ventricle 104. The shaft 14, coupled to the anchor portion 16, may extend into the left ventricle 104. The shaft 14 may further extend at least partially within the mitral valve 108, i.e., the shaft may extend at least partially between the cusps of the mitral valve, and may also extend at least partially into the left atrium 106. The valve body 12 of the mitral valve implant 10 may be positioned at least partially within the left ventricle 104 with the enlarged portion 20 within the left ventricle 104 and with the narrow portion 18 positioned at least partially within and/or pointed towards the left atrium 106.
FIG. 2 depicts the heart 102 in a condition in which the pressure of blood within the left atrium 106 is at equal to, or higher than, the pressure of blood within the left ventricle 104, e.g., during contraction of the left atrium 106. As shown, when the pressure of blood within the left atrium 106 is greater than or equal to the pressure of blood within the left ventricle 104, blood may flow from the left atrium 106 into the left ventricle 104. The pressure differential and/or the flow of blood from the left atrium 106 to the left ventricle 104 may slidably translate the valve body 12 along the shaft 14 toward the left ventricle 104, in the direction of blood flow between the chambers.
Sliding translation of the valve body 12 along the shaft 14 may at least partially withdraw the valve body 12 from the mitral valve 108 to an open position, as shown.
When the valve body is at least partially withdrawn from the mitral valve 108, a passage may be opened between the valve body 12 and the mitral valve 108, allowing blood to flow from the left atrium 106 to the left ventricle 104. Translation of the valve body 12 away from the mitral valve 108 may be controlled and/or limited by the stop 30. In the open position, the stop 30 may maintain the valve body 12 in general proximity to the mitral valve 108 while still permitting sufficient clearance between the mitral valve 108 and the valve body 12 to permit adequate blood flow from the left atrium 106 to the left ventricle 104. Additionally, the flow of blood from left atrium to the left ventricle may cause the mitral valve to flare and/or expand outwardly away from the mitral valve implant, permitting blood flow between the implant and the cusps of the mitral valve.
As the left ventricle 104 contracts, the pressure of blood in the left ventricle 104 may increase such that the blood pressure in the left ventricle 104 is greater than the blood pressure in the left atrium 106. Additionally, as the pressure of the blood in the left ventricle 104 initially increases above the pressure of the blood in the left atrium 106, blood may begin to flow towards and/or back into the left atrium 106. The pressure differential and/or initial flow of blood from the left ventricle 104 into the left atrium 106 may act against the valve body 12 and may translate the valve body 12 toward the left atrium 104. For example, pressurized blood within the left ventricle 104 may act against the bottom 24 of the valve body 12 inducing sliding translation of the valve body 12 along the shaft 14 toward the left atrium 106.
Turning to FIG. 3, the mitral valve implant 10 is shown in a closed position.
In the closed position the valve body 12 may be translated toward and/or at least partially into the left atrium 106. At least a portion of the valve body 12 may interact with, engage, and/or be positioned adjacent to at least a portion of the mitral valve 108. For example, at least a portion of at least one cusp of the mitral valve 108 may contact at least a portion of the valve body 12.
Engagement between the valve body 12 and the mitral valve 108 may restrict and/or prevent the flow of blood from the left ventricle 104 back into the left atrium 106.
In addition to the translation of the valve body 12, the mitral valve 108 may also at least partially close around the valve body 12, thereby also restricting and/or preventing the flow of blood from the left ventricle 104 to the left atrium 106. For example, as mentioned above, at least a portion of one or both of the cusps of the mitral valve may contact at least a portion of the valve body. In some embodiments, as the pressure of the blood in the left ventricle 104 increases, the pressure against the bottom 24 of the valve body 12 may increase. The increase in pressure against the bottom 24 of the valve body 12 may, in turn, increase the engagement between the valve body 12 and the mitral valve 108.
Sliding translation of the valve body 12 toward the left atrium 106 may at least partially be controlled and/or limited by the stop 28 coupled to the shaft 14.
Additionally, translation of the valve body 12 toward the left atrium 106 may be at least partially limited and/or controlled by engagement between the valve body 12 and the mitral valve 108. One or both of these restrictions on the translation of the valve body 12 may, in some embodiments, prevent the valve body 12 from passing fully into the left atrium 106. Furthermore, the diameter of the enlarged portion 20 of the valve body 12 may limit and/or restrict the movement of the valve body 12 into the left atrium 106.
The preceding embodiment may, therefore, provide a mitral valve implant that is slidably translatable relative to the mitral valve to reduce and/or eliminate regurgitation. Further embodiments of a mitral valve implant having a translating valve body may be provided including various alternative valve body configurations. For example, in one embodiment a valve body may be provided generally configured as a disc including generally planar or arcuate top and bottom surfaces. In the same manner as the illustrated embodiment of FIGS. 1-3, the disc may translate along a shaft between an open position spaced from the mitral valve of the heart and closed position at least partially engaging the mitral valve and/or at least partially obstructing a flow of blood from the left ventricle to the left atrium.
Implants employing a valve body having various other geometries, such as spherical, oblong, etc., may also suitably be employed. Furthermore, in addition to the slidably translatable valve body depicted in FIGS. 1-3, embodiments may be provided in which the valve body is rotatably and/or pivotally translatable to engage and/or interact with at least a portion of the mitral valve.
The illustrated mitral valve implant is shown including only a single anchor portion coupled to a proximal end of the shaft. A mitral valve implant consistent with the present disclosure may include more than one anchor portion for securing the mitral valve implant to native coronary tissue. Additional anchor portions may be employed to provide more secure coupling of the valve implant to coronary tissue. Furthermore, more than one anchor portion may be employed to achieve more precise positioning of the valve implant and/or the valve body portion of the valve implant within the heart. For example, a replacement valve may include an anchor portion coupled to the proximal end of the shaft and to the distal end of the shaft. In such an embodiment, each end of the shaft may be coupled to native coronary tissue.
The orientation of the shaft, and thereby the path of translation of the valve body, may be controlled by coupling each end of the shaft to native coronary tissue. In a similar embodiment, the valve implant may include an anchor portion coupled to one end of the shaft and may include another anchor portion coupled to the shaft between the ends thereof.
A valve implant may be produced from a variety of suitable materials.
Generally, such materials may be biocompatible. Suitable materials may include biocompatible polymers, such as silicone, polyurethane, etc. Various metals may additionally be used in connection with a valve implant, such as titanium, stainless steel, etc. Additionally, biological materials and/or materials which may promote cellular ingrowth may also be used in connection with a valve implant herein. Furthermore, various combinations of materials may be used herein, e.g., providing composite features and/or portions made from different materials.
For example, the shaft may be formed from a metal and the valve body may be formed from a polymeric material.
Various additional and/or alternative combinations may also be employed herein.
Turning to FIG. 4, another embodiment of a mitral valve implant 200 is depicted. The mitral valve implant 200 generally includes a valve body portion 202 coupled to a shaft 204.
The shaft 204 may be coupled to an anchor 206. The valve body 202 may be coupled to the shaft 204 in a stationary fashion, e.g., the valve body may be coupled to the shaft in a non-slidable manner. Generally, the valve body 202 may be maintained at a generally fixed position on the shaft 204. The mitral valve implant 200 may be implanted in a heart such that the anchor 206 and the shaft 204 may maintain the valve body 202 in a position relative to various aspects of the coronary anatomy. According to one aspect, the anchor 206 and the shaft 204 may maintain the valve body 202 positioned extending at least partially within the mitral valve.
The valve body 202 may be maintained in a stationary position on the shaft 204 in various ways. For example, valve body 202 may be formed directly on the shaft 205.
Additionally and/or alternatively, the valve body 202 may be adhesively bonded, welded, staked, and/or mechanically fastened to the shaft 204. Consistent with other embodiments, the shaft may include one or more stops or features which may prevent and/or limit translation of the valve body along the shaft. For example, the shaft may include a stop closely positioned on either end of the valve body, thereby restricting movement of the valve body. The stops may be fixed and/or may be adjustable along the shaft 204. Various other configurations and/or arrangements may be employed for coupling the valve body 202 in a stationary manner with respect to the shaft 204.
Similar to previous embodiments, the anchor 206 may be provided having a helical or corkscrew shape. The helical anchor 206 may be engaged with coronary tissue by rotating the anchor 206 about the axis of the helix, thereby driving the anchor 206 into native coronary tissue.
Once the anchor has been engaged with native coronary tissue, the anchor 206 may resist axial pull-out from the tissue. The anchor may additionally and/or alternatively be provided having various features and/or configurations. For example, the anchor may be provided having one or more prongs which may pierce and or be embedded in coronary tissue. In one embodiment, the anchor may include a barbed prong which may resist removal of the anchor from the coronary tissue. The anchor may also be provided having suturing features. For example, the anchor may include a tab and/or ring, etc., through which a suture may pass to secure the anchor coronary tissue.
Turning to FIG. 5, the mitral valve implant 200 is shown implanted within a heart 102.
The mitral valve implant 200 may be positioned extending at least partially into and/or through the mitral valve 108 between the left ventricle 104 and the left atrium 106.
As shown, when the pressure of blood in the left atrium 106 is higher than the pressure of blood in the left ventricle 104, for example during contraction of the left atrium 106, the mitral valve 108 may be in an open condition. In an open condition, blood may flow from the left atrium 106 through the mitral valve 108 and around the valve body 202 and into the left atrium 104.
The anchor 206 may be engaged in native coronary tissue surrounding and/or defining at least a portion of the left ventricle 104. The valve body 202 may be positioned extending at least partially into and/or through the mitral valve 108 by the shaft 204 extending between the anchor 206 and the valve body 202. In a related embodiment, the anchor may be engaged in tissue surrounding and/or defining at least a portion of the left atrium. Similar to the preceding embodiment, the valve body 202 may be positioned extending at least partially into and/or through the mitral valve 108 by the shaft 204 extending between the anchor 206 and the valve body 202.
Consistent with a further embodiment, the mitral valve implant may include more than one anchor for positioning the valve body relative to the mitral valve. For example, the shaft may include an anchor coupled to each end of the shaft. The shaft may be provided extending through the mitral valve, with one anchor being engaged with coronary tissue on the ventricle side of the mitral valve. The other anchor may be engaged with coronary tissue on the atrium side of the mitral valve. As with the previous embodiments, the valve body may be coupled in a stationary position on the shaft, such that the valve body is positioned extending at least partially into and/or at least partially through the mitral valve.
FIG. 6 depicts the mitral valve implant 200 implanted in a heart 102 with the mitral valve 108 in a closed condition. The closed condition of the mitral valve 108 may occur when the pressure of blood in the left ventricle 104 is higher than the pressure of blood in the left atrium 106. As shown, when the mitral valve 108 is in a closed condition at least a portion of the mitral valve 108 may interact with, engage, and/or seal against the valve body 202 of the mitral valve implant 200. The presence of the mitral valve implant 200 may reduce the amount of closure of the mitral valve 108 that is necessary to achieve an adequate seal to permit ejection of blood from the ventricle 104 through the aorta 208, i.e., to prevent and/or reduce mitral regurgitation.
The valve body 202 may be shaped to facilitate the flow of blood from the left atrium 106 to the left ventricle 104 when the mitral valve 108 is open. The valve body 202 may have a generally streamlined shape, allowing the smooth flow of blood around the valve body 202.
Other embodiments of the mitral valve implant may provide less consideration for the flow characteristics of blood flowing around the valve body. The valve body may have a generally cylindrical, prismatic, etc. shape, without limitation.
The performance of the mitral valve implant 200 for reducing and/or eliminating mitral valve regurgitation may be, at least in part, related to the positioning of valve body 202 relative to the mitral valve 108. In an embodiment consistent with this aspect, during implantation of the mitral valve implant, the valve body 202 may be slidably positionable along the shaft 204. Once the anchor 206 is engaged with native coronary tissue the valve body 202 may be translated along the shaft 204 and may be positioned relative to the mitral valve 108, e.g., such that the valve body 202 extends at least partially within the mitral valve 108.
Slidable positioning of the valve body 202 along the shaft 204 after the mitral valve implant 200 has been delivered to the heart 102 may allow the performance of the mitral valve implant 200 to be adjusted.
Furthermore, the adjustability of the position of the valve body 202 may accommodate any errors in the position of the anchor 206 in the heart 102, and/or may render the successful implantation of the mitral valve implant 2001ess dependent upon accurate placement of the anchor 206. Once the valve body 202 has been positioned, the position of the valve body 202 on the shaft 204 may be fixed, e.g. by frictional engagement between the valve body 202 and the shaft 204, etc.
The illustrated and described embodiments of the mitral valve implant have utilized an implant body coupled to a shaft. The shaft, as used herein, may be a rigid, semi-rigid. In further embodiments, the shaft may be a flexible member. Consistent with such embodiments, the shaft may be a flexible wire or filament, etc. In some embodiments, the flexible wire or filament may be coupled to at least two anchor portions. For example, the flexible wire or filament may extend through the valve body. An anchor may be coupled to the flexible wire or filament on each side of the valve body. For example, the flexible wire or filament may position the valve body relative to the mitral valve and may be coupled to the left ventricle and to the left atrium, on either side of the valve body.
An embodiment of a mitral valve implant including a flexible wire and/or filament may suitably be employed in embodiments including a translating valve body, in which the valve body may slidably translate along the flexible wire or filament. In a related embodiment, the valve body may be non-slidably coupled to the flexible wire or filament. The flexible wire or filament may be provided having a length which may permit the valve body to move toward and away from the mitral valve utilizing the flexibility of the flexible wire or filament.
Furthermore, an embodiment of a mitral valve implant including a flexible wire or filament may also suitably be employed in an embodiment including a generally stationary implant body. According to such an embodiment, the implant body may be generally non-slidably coupled to the flexible wire or filament. The flexible wire or filament may be coupled to native coronary tissue, e.g., via anchor portions, etc., on either side of the valve body. Coupling the flexible wire or filament on either side of the valve body may generally maintain the valve body in a position within and/or relative to the mitral valve.
Turning to FIG. 7, another embodiment of a mitral valve implant 200a is shown.
Similar to the previously described embodiment, the mitral valve implant 200a may generally include a valve body 202 configured to reduce and/or eliminate mitral valve regurgitation. In contrast to the preceding embodiment, an anchor 206 may be coupled to the valve body 202.
As shown, the anchor 206 may be directly coupled to the valve body 202 without a shaft extending between the anchor 206 and the valve body 202.
As mentioned above, various different features and/or arrangements may be used for attaching and/or securing the mitral valve implant relative to coronary anatomy. FIG. 8 depicts another embodiment of a mitral valve implant 200b according to the present disclosure including an alternative anchor 206a. As shown, the mitral valve implant 200b may include a valve body 202 coupled directly to the anchor 206a. Alternatively, the valve body may be indirectly coupled to the anchor, e.g., by a shaft. The anchor 206a may generally include one or more prongs, stems, etc. 205. The prong 205 may include one or more barbs 207. The mitral valve implant 200b may be attached and/or secured to native coronary tissue by piercing the anchor 206a at least partially into native coronary tissue. The one or more barbs 207 may engage the coronary tissue and resist removal of the anchor 206a from the coronary tissue.
In a related embodiment, an anchor including one or more barbs may be employed in connection with a translating mitral valve implant configuration, as shown and described herein.
In such and embodiment, the valve body may be translatable relative to the native mitral valve.
For example, the valve body may be coupled to the anchor by a shaft extending therebetween.
The valve body may be slidable along the shaft, permitting the valve body the translate relative to the mitral valve. Various alternative and/or additional related embodiments may also be provided consistent with this aspect of the present disclosure.
Turning to FIG. 9, another embodiment of a movable and/or translatable mitral valve implant l0a is depicted. Similar to the previously described embodiment, the mitral valve implant 10 may generally include a valve body 12 slidably coupled to a shaft 14. The mitral valve 10a may further include an anchor 16 coupled to the shaft 14 and configured to secure and/or attach the mitral valve implant l0a to native coronary tissue. As shown in broken line, the mitral valve implant l0a may include a single stop 29 configured to restrict and/or control the range of movement of the valve body 12 along the shaft 14. As shown, the stop 29 may be disposed at least partially within the valve body 12 and the range of movement of the valve body 12 may be restricted by an interaction between the stop 29 and an inner wall and/or portion of the valve body 12.
As shown, the shaft 14 may extend at least partially though the valve body 12, e.g., through respective openings 26 and 27 at opposed ends of the valve body 12.
The stop 29 may be an enlarged region of the shaft 14, and/or a bead or other member disposed on the shaft 14.
The stop 29 may be dimensioned to prevent and/or restrict passage of the stop 29 through one or both of the openings 26, 27 in the valve body 12. The valve body 12 may, therefore, translate along the shaft 14 with the range of movement being controlled and/or restricted by the interaction of the stop 29 and the openings 26, 27 and/or with an interior wall of the valve body 12.
According to one embodiment of a mitral valve implant 10a including a single stop 29 for controlling the range of movement of the valve body 12, the stop 29 may be installed inside of the valve body by elastically deforming one of the openings 26, 27 over the stop 29. One of the openings 26, 27 may be elastically deformed by pushing the stop against the opening 26, 27 causing the valve body 12 to deform and the opening 26, 27 to expand to permit entrance of the stop 29 into the valve body 12. The valve body 12 may subsequently at least partially elastically recover to resist subsequent removal of the stop 29 from the valve body 12.
Deformation and/or elastic recovery of the valve body 12 may be aided by heating the valve body and/or the stop. In a related embodiment, the stop may also and/or alternatively elastically deform to permit assembly of the mitral valve implant. Various additional and/or alternative methods may also be employed for forming a mitral valve implant including a single stop for restricting and/or controlling the range of movement of the valve body.
A mitral valve implant according to the present disclosure may be implanted using a variety of surgical an/or non-surgical procedures and/or minimally invasive surgical procedures.
A surgical implantation procedure may include, for example, an open heart procedure in which the implant may be directly placed into the heart and manually positioned relative to the mitral valve.
A mitral valve implant consistent with the present disclosure may also advantageously be implanted using less invasive procedures. For example, the mitral valve implant may be implanted using a percutaneous procedure. A suitable percutaneous implantation procedure may include a catheterization procedure. Generally, in a percutaneous catheterization procedure the mitral valve implant may be delivered to the heart using a catheter inserted into a vein or artery, depending upon the desired delivery sight, and into the left atrium or the left ventricle. In one such embodiment, the mitral valve implant may be delivered via a transceptal approach, in which the catheter is inserted, e.g., via a vein, into the right atrium. The catheter may then pass through a puncture between the right atrium to the left atrium and further through the mitral valve to the left ventricle, if desired. Generally, according to a catheterization procedure, the vein or artery may be accessed through a percutaneous incision or puncture. A catheter carrying the mitral valve implant may be introduced into the vein or artery through the incision or puncture. The catheter and mitral valve implant may be passed through the vein or artery into the heart. Once in the heart, the mitral valve implant may be deployed from the catheter and positioned within and/or between the left ventricle and the left atrium.
Turning next to FIG. 10, an embodiment of a percutaneous delivery system 300 for a mitral valve implant 301 is shown. As previously described, the mitral valve implant 301 may generally include a valve body 302 and an anchor 306. According to some embodiments, the mitral valve 301 may further include a shaft 304 which is coupled between the valve body 302 and the anchor 306. As depicted, the mitral valve implant 301 may be loaded into a catheter 308. According to a further embodiment, the mitral valve implant may be carried by a conveyance feature, such as an enlarged region of a catheter and/or a chamber or pod couple to the catheter.
As generally outlined above, with the mitral valve implant 301 loaded in the catheter 308 and/or within a conveyance feature associated with the catheter, at least a portion of the catheter 308 may be inserted into a vein or artery and passed through the vessels, i.e., veins and/or arteries, to the heart. Conveyance of the catheter 308 and/or of the mitral valve implant 301 to the heart may be directed and/or assisted by monitoring the travel of the catheter 308, e.g., via radiographic and/or other imaging techniques, etc. For example, at least a portion of the catheter 308 and/or at least a portion of the mitral valve implant 301 may include a radio-opaque material, allowing the position of the catheter 308 and/or of the mitral valve implant 301 to be radiographically monitored or determined.
Once the mitral valve implant 301 has been delivered to the heart, the mitral valve implant 301 may be implanted by positioning and securing the implant 301 within the heart and deploying the implant 301 from the catheter 308. The implant 301 may be secured within the heart by engaging the anchor 306 with native coronary tissue. Utilizing a helical anchor 306, as shown, the mitral valve implant 301 may be secured by pressing the anchor 306 into coronary tissue and rotationally advancing the anchor 306 into coronary tissue.
Rotationally advancing the anchor 306 may be achieved by rotating the entire catheter 308, and or at least a portion of the catheter 308, and thereby also rotating the anchor 306 relative to the coronary tissue.
Alternatively, the anchor and/or the entire mitral valve implant may be rotated independently of the catheter, e.g., by a drive lead, such as a flexible drive shaft, extending through at least a portion of the catheter and coupled to the mitral valve implant and/or coupled to the anchor.
According to various other embodiments, the anchor of the mitral valve implant may include suturing features, barbs and/or prongs, etc. Suitable corresponding operations may be employed for engaging such anchor features with native coronary tissue.
The mitral valve implant 301 may be deployed from the catheter 308, or other conveyance feature by pushing the mitral valve implant 301 from the catheter.
For example, a pushrod 310, etc., may extend through at least a portion of the catheter 308.
The pushrod 310 may be axially advanced through the catheter 308 to force the mitral valve implant 301 from the lumen of the catheter 308. In a related embodiment, the mitral valve implant may be deployed from the catheter via hydraulic force. For example, a fluid may be forced through the catheter.
The fluid may bear on, and may hydraulically eject the mitral valve implant from the catheter. In still a further embodiment, the mitral valve implant may be pulled from the catheter. The anchor may be engaged with coronary tissue, and the catheter may be withdrawn from the anchor site, leaving the mitral valve implant engaged with the coronary tissue.
Combinations of the foregoing deployment techniques, as well as other known deployment techniques, may also suitable be employed.
The mitral valve implant 301 may be positioned relative to the coronary anatomy before, during or after deployment of the mitral valve implant 301 from the catheter 308. For example, the anchor portion 306 of the mitral valve implant 301 may be engaged with coronary tissue.
The valve body 302 and shaft 304 may then be positioned relative to coronary anatomy by manipulation of the catheter 308, etc. Once the mitral valve implant 301 has been arranged relative to coronary anatomy, the mitral valve implant 301 may be fully deployed from the catheter 308. Alternatively, the mitral valve implant 301 may be fully deployed from the catheter 308. Following deployment, the mitral valve implant 301 may be manipulated to achieve a position and/or arrangement relative to coronary anatomy. Consistent with such an embodiment, the anchor 306 of the mitral valve implant 301 may be engaged with coronary tissue before, during, or after complete deployment of the mitral valve implant 301. Various other techniques and methods may also suitably be employed.
At least a portion of the mitral valve implant 301 may be collapsible and/or reducible in volume to facilitate percutaneous and/or transluminal delivery. In such a manner, the valve body 302 of the mitral valve implant 301 may be a collapsible member, which can be reduced in volume and/or reduced in maximum diameter during delivery to the heart and/or during placement and/or attachment of the anchor to native coronary tissue. After delivery to the heart, the valve body 302 may be expanded, inflated, and/or otherwise increased in volume or size.
Accordingly, the mitral valve implant 301 may be delivered to an implantation site via a smaller diameter catheter, and/or via smaller vessels, than would otherwise be required.
With reference to FIG. 11, according to one embodiment, the mitral valve implant may include an inflatable valve body 402. An inflatable valve body 402 may include an at least partially deformable body 404 defining at least one cavity 406. The body 404 may further define an opening 408 capable of receiving at least a portion of a shaft 410 therein.
Additionally or alternatively, the body may include one or more features for coupling the body to a shaft.
The at least partially deformable valve body 404 may be collapsed to a reduced size, which may, for example, allow the valve body 404 to be loaded into a catheter delivery system.
Such a catheter delivery system may be suitable for transluminal delivery of a mitral valve implant, including the inflatable valve body 402, to the heart. In addition to being collapsed, the valve body 402 may be deformed to facilitate loading into a catheter delivery system. For example, the valve body 402 may be collapsed and may be rolled and/or folded to a generally cylindrical shape, allowing the valve body 402 to be loaded in a catheter having a circular lumen.
A collapsed and/or rolled or folded valve body 402 may be inflated, restoring the valve body 402 to expanded configuration. For example, a collapsed and/or rolled or folded valve body 402 may be inflated and restored to an expanded configuration once the mitral valve implant has been delivered to the heart and deployed from a catheter delivery system. Inflating the valve body 402 may be carried out by introducing a fluid, such as saline, into the at least one cavity 406. In addition to a liquid, such as saline, the valve body may be inflated with a setting or curable fluid. The setting or curable fluid may set and/or be cured to a solid and/or semi-solid state within the cavity of the valve body. An example of such a material may be a thermoset polymer resin, a gel material, such as silicone gel, etc.
According to one embodiment, after delivery to the heart and deployment from the catheter delivery system, the at least one cavity may be filled with a fluid by injecting the fluid into the cavity via a filling tube extending through and/or with the catheter delivery system.
Other filling methods and systems may also suitably be employed herein. In an inflated state, the valve body may be shaped and/or configured for use in connection with a translating and/or a stationary mitral valve implant, as described previously.
According to another embodiment, shown in FIG. 12, the valve body 502 may be expandable. An embodiment of an expandable valve body 502 suitable for use in connection with a mitral valve implant herein may include a recoverably deformable shell 504 defining the shape of the valve body 502. Similar to previous embodiments, the valve body 502 may include an opening 506 for receiving a shaft 508 of a mitral valve implant at least partially therein.
According to one embodiment, the opening 506 may provide a passage extending through the valve body 502. Additionally and/or alternatively, the valve body may include features for coupling the valve body to the shaft.
The recoverably deformable shell 504 may be deformable, for example, to permit the valve body 502 to be collapsed, folded, rolled, etc., for loading into a catheter delivery system, and/or to facilitate delivery of a mitral valve implant including the valve body 502 to an implantation site, e.g., within the heart. The recoverably deformable shell 504 may further be recoverable, allowing the valve body 502 to return to the expanded configuration from a deformed configuration.
Consistent with one aspect, the deformable she11504 may include a resiliently deformable material, such as an elastomer, which may be elastically deformed under stress. The deformable she11504 may elastically recover when the stress is removed. In such an embodiment, the deformable she11504 may, for example, be deformed from an expanded configuration to a collapsed condition and loaded into a catheter delivery system. After delivery to an implant site, the deformable shell 504 may be deployed from the catheter delivery system, thereby removing the deforming stress from the valve body 502. Once the deforming stress is removed, the deformable shell 504 may resiliently recover back to the expanded configuration.
In a related embodiment, the deformable shell may include a shape memory material, such as Nitinol, etc. The deformable shell may be collapsed and/or deformed to facilitate delivery of the implant to the desired site, e.g., via a transluminal and/or a surgical procedure.
The deformable shell may subsequently be recovered to an expanded configuration. In an embodiment using a thermally activated shape memory material, recovery of the shape memory deformable shell may be accomplished by heating the deformable shell to, or above, an activation temperature. Heat for activating the shape memory material may be provided by the body temperature of the subject receiving the mitral valve implant, and/or from an external source, e.g., via the catheter, etc.
An embodiment of mitral valve implant may include an expandable/recoverable valve body including a cellular material. The cellular material may be, for example, a deformable and/or compressible expanded material, such as a polymeric foam material. The valve body may be deformed, compressed, and/or collapsed to a reduced volume configuration, at least in part, by compressing or deforming the cellular material. The mitral valve implant may be transported to an implant site as disclosed. When the implant is deployed from the delivery system the valve body may recover to a generally original volume and/or configuration. Recovery of the valve body may include recovery and/or expansion of the cellular material.
In another related embodiment, depicted in FIG. 13, an expandable valve body 602 may include deformable and/or flexible outer she11604. The outer shell 604 may be supported in an expanded configuration by one or more recoverably deformable supports. In the embodiment of FIG. 13, the recoverably deformable support may be provided as a resiliently deformable rib 606. The deformable she11604 may be a resiliently deformable material and/or may be a flexible material. The resiliently deformable rib 606 and/or the deformable she11604 may be deformed, e.g., to collapse the valve body 602 from an expanded configuration, under a deforming stress.
As discussed with reference to other embodiments, collapsing the valve body 602 may facilitate transport to an mitral valve implant, for example, using a catheter delivery system. When the deforming stress is released, e.g., by deploying the valve body 602 from a delivery system, the recoverably deformable rib 606 and/or the deformable outer shell 604 may resiliently recover to restore the valve body 602 to an expanded condition. While only a single rib is depicted in the illustrated embodiment, the valve body may alternatively include a plurality of recoverably deformable ribs.
In various embodiments, the recoverably deformable supports may be configured as ribs, generally having a transverse orientation relative to the axis of the valve body, such as depicted in FIG. 13. In additional and/or alternative embodiments, a valve body 702 may include a deformable and/or flexible outer shell (not shown) covering and/or supported by recoverably deformable supports in the form of resiliently deformable stringers 704. As depicted in FIG. 14, the recoverably deformable stringers 704 may be generally oriented along the longitudinal axis of the valve body 702. In a further embodiment, the recoverably deformable supports may be configured as a lattice, scaffolding, etc. supporting a deformable and/or flexible outer shell of the valve body. Further embodiments may include combinations ribs and stringers.
Various other configurations of recoverably deformable supports may also suitably be employed.
In addition to resiliently recoverable shell, supports, etc., a mitral valve implant may include a valve body having an outer shell and/or having supports which may be controllably recoverable. For example, an outer shell and/or one or more supports of a mitral valve implant valve body may be formed from a shape memory material. Such materials may include shape memory metal alloys, shape memory polymers, etc. Consistent with such embodiments, the valve body may be collapsed and/or otherwise deformed from an expanded configuration. The collapsed and/or deformed valve body may maintain the collapsed and/or deformed configuration after the initial deforming stress is released. The valve body may subsequently be returned to the expanded and/or operable configuration, for example, by heating the valve body above an activation temperature of the shape memory material, which may induce recovery of the shape memory material to a pre-deformed shape. The activation temperature inducing recovery of the deformed valve body may be provided by the body temperature of the patient receiving the mitral valve implant. Alternatively, heat for activating recovery of the shape memory material may be provided by a heating element coupled to the valve body and/or a heating element delivered through a catheter. In other embodiments, activating heat may be provided by irradiating the shape memory material, e.g., with microwaves, IR
light, etc.
Another embodiment of a valve body 800, suitable for use in a mitral valve implant, is shown in FIG. 15. The valve body 800 may include first and second enlarged portions 802, 804 joined by a narrow region 806. In one such embodiment, the valve body may have a generally hourglass shape, as shown. The valve body 800 may be positioned relative to a mitral valve such that the first enlarged portion 802 may be disposed at least partially within the left atrium and the second enlarged portion may be disposed at least partially within the left ventricle. The valve body may be maintained in position relative to the coronary anatomy by an anchor and/or a shaft consistent with any preceding embodiment. Additionally, the valve body 800 may be a collapsible and/or expandable member consistent with any previously discussed embodiment.
Referring now to FIGS. 16A-16B, another embodiment of a mitral valve implant 900 is shown. Mitral valve implant 900 generally includes expandable member 902, shaft 904 and anchor 906. Expandable member 902 may be an inflatable member capable of expanding or contracting in order to conform with portions of the mitral valve. For example, expandable member 902 may expand until the exterior surface "e" of expandable member 902 approaches or conforms with one or more of the leaflets and/or cusps of the mitral valve.
Expandable member 902 may include a central portion 903, proximal end 905 and distal end 907. Ends 905, 907 of expandable member 902 may each be tapered and configured to form an opening capable of allowing shaft 904 to pass therethrough. This opening could be configured into a variety of different geometries including, but not limited to, circular, square, oval, etc. Ends 905, 907 may be configured to form a seal around shaft 904 in order to prevent the inflation medium from escaping before, during or after inflation. In some embodiments, proximal end 905 may be connected to a connecting member 908, which may include a valve portion (not shown) for insufflation/deflation. Proximal and distal ends 905, 907 may be expandable, however, in other embodiments proximal and distal ends 905, 907 may be constructed out of a rigid non-expandable material, leaving an expandable central portion 903.
Expandable member 902 may include central portion 903 as well as proximal and distal ends 905, 907. Central portion 903 may be monolithically formed with proximal and distal ends 905 and 907. Alternatively, central portion 903 may be configured to connect with proximal and distal ends 905 and 907 to form a seal. Expandable member 902 may be constructed out of a variety of different materials. Some expanding materials may include polymeric materials, elastomeric materials, rubber, latex, chloroprene, nylon fabrics, or any other suitable materials.
The exterior surface "e" of expandable member 902 may be smooth or rough and may include ridges or irregular contours capable of receiving portions of the mitral valve. In some embodiments, the exterior surface of expandable member 902 may include a fabric material capable of contacting and interacting with the leaflets of the mitral valve.
In some embodiments, central portion 903 may also include a coating, which may provide a non-stick surface. Central portion 903 may include other materials as well including, but not limited to, fabric materials, microfibers, nanomaterials, etc. Ends 905 and 907 may include similar materials.
In some embodiments, shaft 904 may be securely attached to the proximal and/or distal ends 905, 907 of expandable member 902. This attachment may be achieved using welding or any other suitable connection. Shaft 904 may also include anchor portion 906, which may be constructed in a variety of different configurations such as the helical arrangement described hereinabove. In some embodiments, expandable member 902 may be slidably movable about shaft 904. For example, expandable member 902 may slide about shaft 904 in a distal direction until reaching anchor portion 906. Similarly, expandable member 902 may be configured to slide in a proximal direction before coming into contact with connecting member 908. Stops, such as those described herein, may be employed to limit the axial movement of expandable member 902. In some embodiments, expandable member 902 may be adjusted and placed in different positions along shaft 904. For example, shaft 904 may include ridges or other adjustment mechanisms capable of forming an interface with ends 905 and 907 of expandable member 902. Using this type of arrangement, expandable member 902 may be adjusted to a number of different positions along shaft 904. Shaft 904 may be constructed out of a variety of different materials and may be rigid or flexible in nature. Moreover, shaft 904 may be hollow and may further include a variety of apertures capable of transporting an inflation medium to the interior "i" of expandable member 902. In some embodiments, the hollow shaft may receive an inflation medium from a hose affixed to connecting member 908. Upon entering the hollow shaft this medium may travel in a distal direction until reaching the plurality of apertures, at which point the medium may exit shaft 904 and insufflate the interior of expandable member 902. Shaft 904 may be entirely solid or entirely hollow or may include both solid and hollow portions. For example, shaft 904 may be hollow until the distal end 907 of expandable member 902 is reached and solid thereafter.
Connecting member 908 may establish a connection between expandable member 902 and a conduit (not shown) such as a hose or other device. This conduit may be connected to an inflation device in order to provide the necessary expansion to expandable member 902.
Expandable member 902 may include pressure sensors and may be capable of indicating the current pressure within the interior of expandable member 902. This information may be provided to the inflation device using telemetry or any other suitable techniques.
Expandable member 902 may be configured to receive a variety of different substances through connecting member 908. These substances may include, but are not limited to, liquids, gases (e.g., air, helium, hydrogen, nitrous oxide), gels, flouro visible materials, etc. Connecting member 908 may be affixed to the conduit and/or expandable member 902 using a variety of different arrangements, including but not limited to, compression fittings, ferrules, screw-fittings, snap-fittings, press-fittings, welding, threaded rod, etc. In some embodiments connecting member 908 may be monolithically formed with expandable member 902 and/or shaft 904.
Connecting member may further include a valve portion (not shown) that may be used to inflate or deflate expandable member 902. Valve portion (not shown) may include but is not limited to, ball-check valves, swing-check valves, clapper valves, stop-check valves and lift-check valves.
Expandable member 902 may be detachably removable from shaft 904 using a variety of different techniques, including, but not limited to, by disconnecting connecting member 908 from shaft 904 and/or expandable member 902. For example, if expandable member 902 is defective or in need of replacement, connecting member 908 may be disconnected and expandable member 902 may be removed and a new valve body may be used as a replacement.
Referring now to FIG. 16B, a cross-sectional view of mitral valve implant 900 is shown.
FIG. 16B shows expandable member 902 having internal layer "i" and external layer "e".
Expandable member 902 defines an internal chamber "c" configured to receive an inflation medium. Internal layer "i" and external layer "e" may each be constructed out of a resiliently deformable material. For example, internal layer "i" may be constructed out of an open or closed cell foam material, which may be compressed into a catheter and delivered to the operative site.
In some embodiments, internal layer "i" may be constructed out of shape memory alloy (e.g., copper-zinc-aluminum, copper-aluminum-nickel, nickel-titanium, etc.) forming a scaffold or strut matrix. Materials having shape memory properties may provide a layer that is capable of moving with expandable member 902 from an initial position to an expanded position and back.
The resiliently deformable properties of expandable member 902 allow exterior layer "e" and interior layer "i" to at least partially conform with the shape of the leaflets of the heart valve.
Interior layer "i" defines an opening or chamber within expandable member 902.
This chamber "c" may be configured to receive an inflation medium from shaft 904. External layer "e" may be disposed over the internal layer "i" as shown in FIG. 16B. External layer "e"
may be constructed out of a variety of different materials, including, but not limited to, expanded PolyTetraFluoroEthylene (EPTFE) and high silicone content, polyurethane copolymers such as ElasteonTM available from AorTech International PLC of the United Kingdom.
Referring now to Figures 17a and 17b mitral valve implant 900 is shown in an initial and expanded position respectively. Implant 900 may be secured to an area of the heart using anchor portion 906. Expandable member 902 may be adjusted axially along shaft 904 until the desired position is reached (e.g., adjusting the depth of anchor portion 906, adjusting via shaft adjustment mechanisms, etc.). At this point an inflation medium may be fed into valve body 902 via a hose or other conduit 950. This medium may cause expandable member 902 to expand away from shaft 904 and possibly create contact with the leaflets of the mitral valve as shown in Figure 17b.
In addition to the circular configuration shown in Figures 16-17, expandable member 902 may include a number of different shapes and configurations. Some possible geometries may include, but are not limited to, round, elliptical, pear shaped, self-shaping, hourglass shaped, etc.
Expandable member 902 may include a uniform or irregular diameter along its length "1". For example, the width "w" of expandable member 902 may increase or decrease along its length "1"
traveling between proximal end 905 and distal end 907.
Referring now to Figure 18, a mitral valve implant 1000 including a pear-shaped expandable member 1002 is shown. Implant 1000 may include shaft 1004, anchor portion 1006, and proximal and distal ends 1005, 1007 as described above. In this embodiment, expandable member 1002 is shown having a tapered configuration, increasing in diameter from a more narrow geometry to a wider geometry as the distal end 1007 of expandable member 1002 is approached. Of course, this tapered configuration could be altered and may include varying degrees of curvature. For example, the diameter of expandable member 1002 could decrease in diameter as the distal end 1007 of expandable member 1002 is approached.
Figure 19 shows another embodiment of a mitral valve implant 1100 having a heart-shaped or partially heart-shaped configuration. Implant 1100 may be positioned between the leaflets of the mitral valve and insufflated until the desired position is obtained. Of course, other shapes and configurations are also envisioned. For example, an additional embodiment of an implant 1200 is depicted in Figure 20. Implant 1200 may include a plurality of ridges "r" or grooves capable of abutting with the mitral valve. The exterior surface of expandable member 1202 may include a variety of different surfaces and surface geometries. For example, ridges, grooves, and/or convex or concave indentations may be provided upon the exterior surface of expandable member 1202 to interact with the leaflets of the mitral valve.
These variations upon the exterior surface may be used in accordance with any of the embodiments described herein.
Figure 21 shows yet another embodiment of a mitral valve implant 1300. Mitral valve implant 1300 may include expandable member 1302, shaft 1304 and anchor portion 1306.
Implant 1300 includes expanded proximal and distal ends 1305 and 1307 that connect via narrow central portion 1303. In some embodiments, implant 1300 may be positioned to allow for any portion of expandable member 1302 to contact the mitral valve. The expansion characteristics of central portion 1303, proximal end 1305 and distal end 1307 may be consistent or irregular. For example, in some embodiments, ends 1305 and 1307 may expand at substantially the same rate while central portion 1303 expands at a slower rate. This may be achieved using different construction methods for each section and/or constructing each section out of different materials or by using varying degrees of thickness. Of course, altering the design and/or material properties of the expandable member may be performed using any or all of the embodiments described herein.
Referring now to Figures 22A and 22B, an additional embodiment of a mitral valve implant 1400 is shown. Mitral valve implant 1400 may include expandable member 1402, shaft 1404 and anchor portion 1406. Figure 22A depicts implant 1400 in an "at rest"
position.
Implant 1400 may further include a plurality of protrusions 1420 connected via linkage portion 1422. Aspects of linkage portion 1422 and protrusions 1420 may be configured to receive an inflation medium and to expand in a transverse direction from shaft 1404.
Protrusions 1420 may be expandable and may be further configured to receive gels or other substances, which may be capable of hardening after entering expandable member 1402. Some substances may maintain a self-shaping property, which may allow portions of expandable member 1402 to conform to the leaflets of the mitral valve. Figure 22B shows an embodiment of implant 1400 in an expanded position. Implant 1400 may be expanded until protrusions 1420 and/or linkage portion 1422 contact the leaflets of the mitral valve.
Figure 23 provides an additional embodiment of mitral valve implant 1500 having a detachable expandable member 1502. Implant 1500 includes connector portion 1508, which may be a screw-fit, snap-fit or any other suitable configuration. In this embodiment, connector portion 1508 may be detached from expandable member 1502 and/or shaft 1504, allowing for the removal and/or replacement of expandable member 1502. In some embodiments, connector portion 1508 and expandable member 1502 may be permanently affixed. If so, the connector portion 1508 and expandable member 1502 may both need to be removed from shaft 1504.
Shaft 1504 and anchor portion 1506 may remain in an anchored position while the existing expandable member is removed and replaced.
In some embodiments, the valve implant described herein may be used as a sizing mechanism in order to determine the approximate distance between the leaflets of the mitral valve. In other words, once the approximate size of the opening is determined via the valve implant a mold having a similar construction may be created and inserted in order to provide a more permanent device.
In some embodiments, the expandable member may be filled with a fluoro-visible material, which may provide the surgeon with improved visibility during the placement of implant. The implant may be positioned in an uninflated state and subsequently inflated after it has been placed in the appropriate position, possibly between the leaflets of the mitral valve.
The fluoro-visible material may remain within the expandable member or may be removed and replaced with an alternative substance.
The implant herein has been disclosed above in the context of a mitral valve implant. An implant consistent with the present disclosure may also suitably be employed in other applications, e.g., as an implant associated with one of the other valves of the heart, etc. The present disclosure should not, therefore, be construed as being limited to use for reducing and/or preventing regurgitation of the mitral valve.
The terms valve body and expandable member, as described herein, may be used interchangeably to refer to a portion of the valve implant that may conform with at least a portion of at least one leaflet of a heart valve. While the depicted embodiments including expandable and/or recoverably deformable valve bodies have generally been shown configured as a expandable member consistent with a stationary valve implant, an expandable and/or recoverably deformable expandable member may be configured for use as part of a valve implant including a translating valve body. Similarly, while the valve implant embodiments including an expandable expandable member have been discussed in connection with transluminal and/or percutaneous delivery systems and/or procedures, such embodiments may also suitably be employed in connection with surgical delivery systems and/or methods. Additionally, other features and aspects of the various embodiments may also suitably be combined and/or modified consistent with the present disclosure. The disclosure herein should not, therefore, be limited to any particular disclosed embodiment, and should be given full scope of the appended claims.
FIG. 22B depicts the mitral valve implant of FIG. 22A shown in an expanded position;
and FIG. 23 is a perspective view of yet another embodiment of a mitral valve implant having a detachable valve body.
DESCRIPTION
The present disclosure relates to a heart valve implant. A heart valve implant herein may suitably be used in connection with the treatment and/or correction of a dysfunctional or inoperative heart valve. One suitable implementation for a heart valve implant consistent with the present disclosure is the treatment of mitral valve regurgitation. For the ease of explanation, the heart valve implant herein is described in terms of a mitral valve implant, such as may be used in treating mitral valve regurgitation. However, a heart valve implant consistent with the present disclosure may be employed for treating and/or correcting other dysfunctional or inoperative heart valves. The present disclosure should not, therefore, be construed as being limited to use as a mitral valve implant.
Generally, a heart valve implant consistent with the present disclosure may interact with at least a portion of an existing heart valve to prevent and/or reduce regurgitation. For example, at least a portion of one or more cusps of the heart valve may interact with, engage, and/or seal against at least a portion of the heart valve implant when the heart valve is in a closed condition.
The interaction, engagement and/or sealing between at least a portion of at least one cusp and at least a portion of the heart valve implant may reduce and/or eliminate regurgitation in a heart valve, for example, providing insufficient sealing, including only a single cusp, e.g., following removal of a diseased and/or damaged cusp, and/or having a ruptured cordae. A
heart valve implant consistent with the present disclosure may be used in connection with various additional and/or alternative defects and/or deficiencies.
Referring to FIG. 1, a perspective view of an embodiment of a mitral valve implant 10 is depicted. In general, the mitral valve implant 10 may be capable of increasing the sealing and/or closure of the passage between the left ventricle and the left atrium during contraction of the left ventricle relative to damaged and/or leaking native valve. Accordingly, in some embodiments the mitral valve implant 10 may be capable of operating in combination with a partially operable and/or damaged mitral valve. That is, the mitral valve implant may interact and/or cooperate with at least a portion of the native mitral valve to reduce and/or eliminate excessive regurgitation. As shown, mitral valve implant may generally include a valve body portion 12 which may be coupled to a shaft 14. The shaft 14 may be coupled to an anchor portion 16.
The valve body portion 12 of the mitral valve implant 10 shown in FIG. 1 may have a generally tapered shape, including a sidewall 17 tapering outwardly from a narrow portion 18 adjacent to one end of the valve body 12 to an enlarged portion 20 adjacent to the other end of the valve body 12. The taper of the sidewall 17 may have a flared or belled shape, providing an at least partially concave geometry, as depicted in FIG. 1. In various other embodiments the valve body may include a sidewall having a generally uniform taper, providing a straight profile.
In still other embodiments, the sidewall of the valve body may exhibit a convex taper, producing an at least somewhat bulging tapered profile.
The enlarged portion 20 of the valve body 12 may have an arcuate profile around the circumference 22 of the proximal region of the enlarged portion 20. The bottom 24 of the enlarged portion 20 may be provided having a flat and/or arcuate shape.
Furthermore, the bottom 24 of the proximal region may include convex and/or concave contours.
According to an embodiment, the valve body 12 may be slidably coupled to the shaft 14.
The valve body 12 may include an opening 26 extending from the bottom 24 of the enlarged portion 20, through the valve body 12, and to the narrow portion 18. In one such embodiment, the opening 26 may extend generally axially through the valve body 12. The opening 26 may be sized to slidably receive at least a portion of the shaft 14 therethrough. The shaft 14 may include one or more stops 28, 30. The stops 28, 30 may be sized and/or shaped to control and/or restrict translation of the valve body 12 along the shaft 14 beyond the respective stops 28, 30. In this manner, in the illustrated embodiment, translation of the valve body 12 along the shaft 14 may be restricted to the expanse of the shaft 14 between the stops 28, 30.
One or more of the stops 28, 30 may be integrally formed with the shaft 14.
Furthermore, one or more of the stops 28, 30 may be provided as a separate member coupled to and/or formed on the shaft 14. In an embodiment in which one or more of the stops 28, 30 are integrally formed with the shaft 14, the valve body 12 may be slidably coupled to the shaft 14 by pressing the valve body 12 over at least one of the stops 28, 30, which may at least partially elastically deform the opening 26 to permit passage of at least one of the stops 28, 30.
Once the one or more of the stops 28, 30 have been pressed through the opening 26, the opening 26 may at least partially elastically recover, thereby resisting passage of the one or more stops 28, 30 back through the opening 26. Various other arrangements may be employed for providing stops on the shaft and/or for controlling and/or limiting translation of the valve body along the shaft.
The anchor portion 16 may include a helical member 32 coupled to the shaft 14.
As shown, the helical member 32 may be loosely wound such that adjacent turns of the helical member 32 do not contact one another, for example resembling a corkscrew-type configuration.
The anchor portion 16 may be engaged with tissue by rotating the anchor portion 16 about the axis of the helical member 32, thereby advancing the anchor portion 16 into tissue. Consistent with such an embodiment, the anchor portion 16 may resist pulling out from the tissue. The anchor portion 16 may be provided as an extension of the shaft 14 wound in a helical configuration. Consistent with related embodiments, the anchor portion 16 may be formed as a separate feature and may be coupled to the shaft 14, e.g., using mechanical fasteners, welding, adhesive, etc.
According to various alternative embodiments, the anchor portion may include various configurations capable of being coupled to and/or otherwise attached to native coronary tissue.
For example, the anchor portion may include one or more prongs adapted to pierce coronary tissue and to alone, or in conjunction with other features, resist removal of the anchor portion from tissue. For example, the anchor portion may include a plurality of prongs which may engage native coronary tissue. According to various other embodiments, the anchor portion may include features that may facilitate attachment by suturing. Exemplary features to facilitate suturing may include rings or openings, suture penetrable tabs, etc. Various other anchor portions that may allow attachment or coupling to native coronary tissue may also suitably be employed in connection with the present disclosure.
Turning to FIGS. 2 and 3, the mitral valve implant 10 is shown implanted within a heart 102. The mitral valve implant 10 may be disposed at least partially within the left ventricle 104 of the heart 102. As shown, the anchor portion 16 may be engaged with native coronary tissue within and/or adjacent to the left ventricle 104. The shaft 14, coupled to the anchor portion 16, may extend into the left ventricle 104. The shaft 14 may further extend at least partially within the mitral valve 108, i.e., the shaft may extend at least partially between the cusps of the mitral valve, and may also extend at least partially into the left atrium 106. The valve body 12 of the mitral valve implant 10 may be positioned at least partially within the left ventricle 104 with the enlarged portion 20 within the left ventricle 104 and with the narrow portion 18 positioned at least partially within and/or pointed towards the left atrium 106.
FIG. 2 depicts the heart 102 in a condition in which the pressure of blood within the left atrium 106 is at equal to, or higher than, the pressure of blood within the left ventricle 104, e.g., during contraction of the left atrium 106. As shown, when the pressure of blood within the left atrium 106 is greater than or equal to the pressure of blood within the left ventricle 104, blood may flow from the left atrium 106 into the left ventricle 104. The pressure differential and/or the flow of blood from the left atrium 106 to the left ventricle 104 may slidably translate the valve body 12 along the shaft 14 toward the left ventricle 104, in the direction of blood flow between the chambers.
Sliding translation of the valve body 12 along the shaft 14 may at least partially withdraw the valve body 12 from the mitral valve 108 to an open position, as shown.
When the valve body is at least partially withdrawn from the mitral valve 108, a passage may be opened between the valve body 12 and the mitral valve 108, allowing blood to flow from the left atrium 106 to the left ventricle 104. Translation of the valve body 12 away from the mitral valve 108 may be controlled and/or limited by the stop 30. In the open position, the stop 30 may maintain the valve body 12 in general proximity to the mitral valve 108 while still permitting sufficient clearance between the mitral valve 108 and the valve body 12 to permit adequate blood flow from the left atrium 106 to the left ventricle 104. Additionally, the flow of blood from left atrium to the left ventricle may cause the mitral valve to flare and/or expand outwardly away from the mitral valve implant, permitting blood flow between the implant and the cusps of the mitral valve.
As the left ventricle 104 contracts, the pressure of blood in the left ventricle 104 may increase such that the blood pressure in the left ventricle 104 is greater than the blood pressure in the left atrium 106. Additionally, as the pressure of the blood in the left ventricle 104 initially increases above the pressure of the blood in the left atrium 106, blood may begin to flow towards and/or back into the left atrium 106. The pressure differential and/or initial flow of blood from the left ventricle 104 into the left atrium 106 may act against the valve body 12 and may translate the valve body 12 toward the left atrium 104. For example, pressurized blood within the left ventricle 104 may act against the bottom 24 of the valve body 12 inducing sliding translation of the valve body 12 along the shaft 14 toward the left atrium 106.
Turning to FIG. 3, the mitral valve implant 10 is shown in a closed position.
In the closed position the valve body 12 may be translated toward and/or at least partially into the left atrium 106. At least a portion of the valve body 12 may interact with, engage, and/or be positioned adjacent to at least a portion of the mitral valve 108. For example, at least a portion of at least one cusp of the mitral valve 108 may contact at least a portion of the valve body 12.
Engagement between the valve body 12 and the mitral valve 108 may restrict and/or prevent the flow of blood from the left ventricle 104 back into the left atrium 106.
In addition to the translation of the valve body 12, the mitral valve 108 may also at least partially close around the valve body 12, thereby also restricting and/or preventing the flow of blood from the left ventricle 104 to the left atrium 106. For example, as mentioned above, at least a portion of one or both of the cusps of the mitral valve may contact at least a portion of the valve body. In some embodiments, as the pressure of the blood in the left ventricle 104 increases, the pressure against the bottom 24 of the valve body 12 may increase. The increase in pressure against the bottom 24 of the valve body 12 may, in turn, increase the engagement between the valve body 12 and the mitral valve 108.
Sliding translation of the valve body 12 toward the left atrium 106 may at least partially be controlled and/or limited by the stop 28 coupled to the shaft 14.
Additionally, translation of the valve body 12 toward the left atrium 106 may be at least partially limited and/or controlled by engagement between the valve body 12 and the mitral valve 108. One or both of these restrictions on the translation of the valve body 12 may, in some embodiments, prevent the valve body 12 from passing fully into the left atrium 106. Furthermore, the diameter of the enlarged portion 20 of the valve body 12 may limit and/or restrict the movement of the valve body 12 into the left atrium 106.
The preceding embodiment may, therefore, provide a mitral valve implant that is slidably translatable relative to the mitral valve to reduce and/or eliminate regurgitation. Further embodiments of a mitral valve implant having a translating valve body may be provided including various alternative valve body configurations. For example, in one embodiment a valve body may be provided generally configured as a disc including generally planar or arcuate top and bottom surfaces. In the same manner as the illustrated embodiment of FIGS. 1-3, the disc may translate along a shaft between an open position spaced from the mitral valve of the heart and closed position at least partially engaging the mitral valve and/or at least partially obstructing a flow of blood from the left ventricle to the left atrium.
Implants employing a valve body having various other geometries, such as spherical, oblong, etc., may also suitably be employed. Furthermore, in addition to the slidably translatable valve body depicted in FIGS. 1-3, embodiments may be provided in which the valve body is rotatably and/or pivotally translatable to engage and/or interact with at least a portion of the mitral valve.
The illustrated mitral valve implant is shown including only a single anchor portion coupled to a proximal end of the shaft. A mitral valve implant consistent with the present disclosure may include more than one anchor portion for securing the mitral valve implant to native coronary tissue. Additional anchor portions may be employed to provide more secure coupling of the valve implant to coronary tissue. Furthermore, more than one anchor portion may be employed to achieve more precise positioning of the valve implant and/or the valve body portion of the valve implant within the heart. For example, a replacement valve may include an anchor portion coupled to the proximal end of the shaft and to the distal end of the shaft. In such an embodiment, each end of the shaft may be coupled to native coronary tissue.
The orientation of the shaft, and thereby the path of translation of the valve body, may be controlled by coupling each end of the shaft to native coronary tissue. In a similar embodiment, the valve implant may include an anchor portion coupled to one end of the shaft and may include another anchor portion coupled to the shaft between the ends thereof.
A valve implant may be produced from a variety of suitable materials.
Generally, such materials may be biocompatible. Suitable materials may include biocompatible polymers, such as silicone, polyurethane, etc. Various metals may additionally be used in connection with a valve implant, such as titanium, stainless steel, etc. Additionally, biological materials and/or materials which may promote cellular ingrowth may also be used in connection with a valve implant herein. Furthermore, various combinations of materials may be used herein, e.g., providing composite features and/or portions made from different materials.
For example, the shaft may be formed from a metal and the valve body may be formed from a polymeric material.
Various additional and/or alternative combinations may also be employed herein.
Turning to FIG. 4, another embodiment of a mitral valve implant 200 is depicted. The mitral valve implant 200 generally includes a valve body portion 202 coupled to a shaft 204.
The shaft 204 may be coupled to an anchor 206. The valve body 202 may be coupled to the shaft 204 in a stationary fashion, e.g., the valve body may be coupled to the shaft in a non-slidable manner. Generally, the valve body 202 may be maintained at a generally fixed position on the shaft 204. The mitral valve implant 200 may be implanted in a heart such that the anchor 206 and the shaft 204 may maintain the valve body 202 in a position relative to various aspects of the coronary anatomy. According to one aspect, the anchor 206 and the shaft 204 may maintain the valve body 202 positioned extending at least partially within the mitral valve.
The valve body 202 may be maintained in a stationary position on the shaft 204 in various ways. For example, valve body 202 may be formed directly on the shaft 205.
Additionally and/or alternatively, the valve body 202 may be adhesively bonded, welded, staked, and/or mechanically fastened to the shaft 204. Consistent with other embodiments, the shaft may include one or more stops or features which may prevent and/or limit translation of the valve body along the shaft. For example, the shaft may include a stop closely positioned on either end of the valve body, thereby restricting movement of the valve body. The stops may be fixed and/or may be adjustable along the shaft 204. Various other configurations and/or arrangements may be employed for coupling the valve body 202 in a stationary manner with respect to the shaft 204.
Similar to previous embodiments, the anchor 206 may be provided having a helical or corkscrew shape. The helical anchor 206 may be engaged with coronary tissue by rotating the anchor 206 about the axis of the helix, thereby driving the anchor 206 into native coronary tissue.
Once the anchor has been engaged with native coronary tissue, the anchor 206 may resist axial pull-out from the tissue. The anchor may additionally and/or alternatively be provided having various features and/or configurations. For example, the anchor may be provided having one or more prongs which may pierce and or be embedded in coronary tissue. In one embodiment, the anchor may include a barbed prong which may resist removal of the anchor from the coronary tissue. The anchor may also be provided having suturing features. For example, the anchor may include a tab and/or ring, etc., through which a suture may pass to secure the anchor coronary tissue.
Turning to FIG. 5, the mitral valve implant 200 is shown implanted within a heart 102.
The mitral valve implant 200 may be positioned extending at least partially into and/or through the mitral valve 108 between the left ventricle 104 and the left atrium 106.
As shown, when the pressure of blood in the left atrium 106 is higher than the pressure of blood in the left ventricle 104, for example during contraction of the left atrium 106, the mitral valve 108 may be in an open condition. In an open condition, blood may flow from the left atrium 106 through the mitral valve 108 and around the valve body 202 and into the left atrium 104.
The anchor 206 may be engaged in native coronary tissue surrounding and/or defining at least a portion of the left ventricle 104. The valve body 202 may be positioned extending at least partially into and/or through the mitral valve 108 by the shaft 204 extending between the anchor 206 and the valve body 202. In a related embodiment, the anchor may be engaged in tissue surrounding and/or defining at least a portion of the left atrium. Similar to the preceding embodiment, the valve body 202 may be positioned extending at least partially into and/or through the mitral valve 108 by the shaft 204 extending between the anchor 206 and the valve body 202.
Consistent with a further embodiment, the mitral valve implant may include more than one anchor for positioning the valve body relative to the mitral valve. For example, the shaft may include an anchor coupled to each end of the shaft. The shaft may be provided extending through the mitral valve, with one anchor being engaged with coronary tissue on the ventricle side of the mitral valve. The other anchor may be engaged with coronary tissue on the atrium side of the mitral valve. As with the previous embodiments, the valve body may be coupled in a stationary position on the shaft, such that the valve body is positioned extending at least partially into and/or at least partially through the mitral valve.
FIG. 6 depicts the mitral valve implant 200 implanted in a heart 102 with the mitral valve 108 in a closed condition. The closed condition of the mitral valve 108 may occur when the pressure of blood in the left ventricle 104 is higher than the pressure of blood in the left atrium 106. As shown, when the mitral valve 108 is in a closed condition at least a portion of the mitral valve 108 may interact with, engage, and/or seal against the valve body 202 of the mitral valve implant 200. The presence of the mitral valve implant 200 may reduce the amount of closure of the mitral valve 108 that is necessary to achieve an adequate seal to permit ejection of blood from the ventricle 104 through the aorta 208, i.e., to prevent and/or reduce mitral regurgitation.
The valve body 202 may be shaped to facilitate the flow of blood from the left atrium 106 to the left ventricle 104 when the mitral valve 108 is open. The valve body 202 may have a generally streamlined shape, allowing the smooth flow of blood around the valve body 202.
Other embodiments of the mitral valve implant may provide less consideration for the flow characteristics of blood flowing around the valve body. The valve body may have a generally cylindrical, prismatic, etc. shape, without limitation.
The performance of the mitral valve implant 200 for reducing and/or eliminating mitral valve regurgitation may be, at least in part, related to the positioning of valve body 202 relative to the mitral valve 108. In an embodiment consistent with this aspect, during implantation of the mitral valve implant, the valve body 202 may be slidably positionable along the shaft 204. Once the anchor 206 is engaged with native coronary tissue the valve body 202 may be translated along the shaft 204 and may be positioned relative to the mitral valve 108, e.g., such that the valve body 202 extends at least partially within the mitral valve 108.
Slidable positioning of the valve body 202 along the shaft 204 after the mitral valve implant 200 has been delivered to the heart 102 may allow the performance of the mitral valve implant 200 to be adjusted.
Furthermore, the adjustability of the position of the valve body 202 may accommodate any errors in the position of the anchor 206 in the heart 102, and/or may render the successful implantation of the mitral valve implant 2001ess dependent upon accurate placement of the anchor 206. Once the valve body 202 has been positioned, the position of the valve body 202 on the shaft 204 may be fixed, e.g. by frictional engagement between the valve body 202 and the shaft 204, etc.
The illustrated and described embodiments of the mitral valve implant have utilized an implant body coupled to a shaft. The shaft, as used herein, may be a rigid, semi-rigid. In further embodiments, the shaft may be a flexible member. Consistent with such embodiments, the shaft may be a flexible wire or filament, etc. In some embodiments, the flexible wire or filament may be coupled to at least two anchor portions. For example, the flexible wire or filament may extend through the valve body. An anchor may be coupled to the flexible wire or filament on each side of the valve body. For example, the flexible wire or filament may position the valve body relative to the mitral valve and may be coupled to the left ventricle and to the left atrium, on either side of the valve body.
An embodiment of a mitral valve implant including a flexible wire and/or filament may suitably be employed in embodiments including a translating valve body, in which the valve body may slidably translate along the flexible wire or filament. In a related embodiment, the valve body may be non-slidably coupled to the flexible wire or filament. The flexible wire or filament may be provided having a length which may permit the valve body to move toward and away from the mitral valve utilizing the flexibility of the flexible wire or filament.
Furthermore, an embodiment of a mitral valve implant including a flexible wire or filament may also suitably be employed in an embodiment including a generally stationary implant body. According to such an embodiment, the implant body may be generally non-slidably coupled to the flexible wire or filament. The flexible wire or filament may be coupled to native coronary tissue, e.g., via anchor portions, etc., on either side of the valve body. Coupling the flexible wire or filament on either side of the valve body may generally maintain the valve body in a position within and/or relative to the mitral valve.
Turning to FIG. 7, another embodiment of a mitral valve implant 200a is shown.
Similar to the previously described embodiment, the mitral valve implant 200a may generally include a valve body 202 configured to reduce and/or eliminate mitral valve regurgitation. In contrast to the preceding embodiment, an anchor 206 may be coupled to the valve body 202.
As shown, the anchor 206 may be directly coupled to the valve body 202 without a shaft extending between the anchor 206 and the valve body 202.
As mentioned above, various different features and/or arrangements may be used for attaching and/or securing the mitral valve implant relative to coronary anatomy. FIG. 8 depicts another embodiment of a mitral valve implant 200b according to the present disclosure including an alternative anchor 206a. As shown, the mitral valve implant 200b may include a valve body 202 coupled directly to the anchor 206a. Alternatively, the valve body may be indirectly coupled to the anchor, e.g., by a shaft. The anchor 206a may generally include one or more prongs, stems, etc. 205. The prong 205 may include one or more barbs 207. The mitral valve implant 200b may be attached and/or secured to native coronary tissue by piercing the anchor 206a at least partially into native coronary tissue. The one or more barbs 207 may engage the coronary tissue and resist removal of the anchor 206a from the coronary tissue.
In a related embodiment, an anchor including one or more barbs may be employed in connection with a translating mitral valve implant configuration, as shown and described herein.
In such and embodiment, the valve body may be translatable relative to the native mitral valve.
For example, the valve body may be coupled to the anchor by a shaft extending therebetween.
The valve body may be slidable along the shaft, permitting the valve body the translate relative to the mitral valve. Various alternative and/or additional related embodiments may also be provided consistent with this aspect of the present disclosure.
Turning to FIG. 9, another embodiment of a movable and/or translatable mitral valve implant l0a is depicted. Similar to the previously described embodiment, the mitral valve implant 10 may generally include a valve body 12 slidably coupled to a shaft 14. The mitral valve 10a may further include an anchor 16 coupled to the shaft 14 and configured to secure and/or attach the mitral valve implant l0a to native coronary tissue. As shown in broken line, the mitral valve implant l0a may include a single stop 29 configured to restrict and/or control the range of movement of the valve body 12 along the shaft 14. As shown, the stop 29 may be disposed at least partially within the valve body 12 and the range of movement of the valve body 12 may be restricted by an interaction between the stop 29 and an inner wall and/or portion of the valve body 12.
As shown, the shaft 14 may extend at least partially though the valve body 12, e.g., through respective openings 26 and 27 at opposed ends of the valve body 12.
The stop 29 may be an enlarged region of the shaft 14, and/or a bead or other member disposed on the shaft 14.
The stop 29 may be dimensioned to prevent and/or restrict passage of the stop 29 through one or both of the openings 26, 27 in the valve body 12. The valve body 12 may, therefore, translate along the shaft 14 with the range of movement being controlled and/or restricted by the interaction of the stop 29 and the openings 26, 27 and/or with an interior wall of the valve body 12.
According to one embodiment of a mitral valve implant 10a including a single stop 29 for controlling the range of movement of the valve body 12, the stop 29 may be installed inside of the valve body by elastically deforming one of the openings 26, 27 over the stop 29. One of the openings 26, 27 may be elastically deformed by pushing the stop against the opening 26, 27 causing the valve body 12 to deform and the opening 26, 27 to expand to permit entrance of the stop 29 into the valve body 12. The valve body 12 may subsequently at least partially elastically recover to resist subsequent removal of the stop 29 from the valve body 12.
Deformation and/or elastic recovery of the valve body 12 may be aided by heating the valve body and/or the stop. In a related embodiment, the stop may also and/or alternatively elastically deform to permit assembly of the mitral valve implant. Various additional and/or alternative methods may also be employed for forming a mitral valve implant including a single stop for restricting and/or controlling the range of movement of the valve body.
A mitral valve implant according to the present disclosure may be implanted using a variety of surgical an/or non-surgical procedures and/or minimally invasive surgical procedures.
A surgical implantation procedure may include, for example, an open heart procedure in which the implant may be directly placed into the heart and manually positioned relative to the mitral valve.
A mitral valve implant consistent with the present disclosure may also advantageously be implanted using less invasive procedures. For example, the mitral valve implant may be implanted using a percutaneous procedure. A suitable percutaneous implantation procedure may include a catheterization procedure. Generally, in a percutaneous catheterization procedure the mitral valve implant may be delivered to the heart using a catheter inserted into a vein or artery, depending upon the desired delivery sight, and into the left atrium or the left ventricle. In one such embodiment, the mitral valve implant may be delivered via a transceptal approach, in which the catheter is inserted, e.g., via a vein, into the right atrium. The catheter may then pass through a puncture between the right atrium to the left atrium and further through the mitral valve to the left ventricle, if desired. Generally, according to a catheterization procedure, the vein or artery may be accessed through a percutaneous incision or puncture. A catheter carrying the mitral valve implant may be introduced into the vein or artery through the incision or puncture. The catheter and mitral valve implant may be passed through the vein or artery into the heart. Once in the heart, the mitral valve implant may be deployed from the catheter and positioned within and/or between the left ventricle and the left atrium.
Turning next to FIG. 10, an embodiment of a percutaneous delivery system 300 for a mitral valve implant 301 is shown. As previously described, the mitral valve implant 301 may generally include a valve body 302 and an anchor 306. According to some embodiments, the mitral valve 301 may further include a shaft 304 which is coupled between the valve body 302 and the anchor 306. As depicted, the mitral valve implant 301 may be loaded into a catheter 308. According to a further embodiment, the mitral valve implant may be carried by a conveyance feature, such as an enlarged region of a catheter and/or a chamber or pod couple to the catheter.
As generally outlined above, with the mitral valve implant 301 loaded in the catheter 308 and/or within a conveyance feature associated with the catheter, at least a portion of the catheter 308 may be inserted into a vein or artery and passed through the vessels, i.e., veins and/or arteries, to the heart. Conveyance of the catheter 308 and/or of the mitral valve implant 301 to the heart may be directed and/or assisted by monitoring the travel of the catheter 308, e.g., via radiographic and/or other imaging techniques, etc. For example, at least a portion of the catheter 308 and/or at least a portion of the mitral valve implant 301 may include a radio-opaque material, allowing the position of the catheter 308 and/or of the mitral valve implant 301 to be radiographically monitored or determined.
Once the mitral valve implant 301 has been delivered to the heart, the mitral valve implant 301 may be implanted by positioning and securing the implant 301 within the heart and deploying the implant 301 from the catheter 308. The implant 301 may be secured within the heart by engaging the anchor 306 with native coronary tissue. Utilizing a helical anchor 306, as shown, the mitral valve implant 301 may be secured by pressing the anchor 306 into coronary tissue and rotationally advancing the anchor 306 into coronary tissue.
Rotationally advancing the anchor 306 may be achieved by rotating the entire catheter 308, and or at least a portion of the catheter 308, and thereby also rotating the anchor 306 relative to the coronary tissue.
Alternatively, the anchor and/or the entire mitral valve implant may be rotated independently of the catheter, e.g., by a drive lead, such as a flexible drive shaft, extending through at least a portion of the catheter and coupled to the mitral valve implant and/or coupled to the anchor.
According to various other embodiments, the anchor of the mitral valve implant may include suturing features, barbs and/or prongs, etc. Suitable corresponding operations may be employed for engaging such anchor features with native coronary tissue.
The mitral valve implant 301 may be deployed from the catheter 308, or other conveyance feature by pushing the mitral valve implant 301 from the catheter.
For example, a pushrod 310, etc., may extend through at least a portion of the catheter 308.
The pushrod 310 may be axially advanced through the catheter 308 to force the mitral valve implant 301 from the lumen of the catheter 308. In a related embodiment, the mitral valve implant may be deployed from the catheter via hydraulic force. For example, a fluid may be forced through the catheter.
The fluid may bear on, and may hydraulically eject the mitral valve implant from the catheter. In still a further embodiment, the mitral valve implant may be pulled from the catheter. The anchor may be engaged with coronary tissue, and the catheter may be withdrawn from the anchor site, leaving the mitral valve implant engaged with the coronary tissue.
Combinations of the foregoing deployment techniques, as well as other known deployment techniques, may also suitable be employed.
The mitral valve implant 301 may be positioned relative to the coronary anatomy before, during or after deployment of the mitral valve implant 301 from the catheter 308. For example, the anchor portion 306 of the mitral valve implant 301 may be engaged with coronary tissue.
The valve body 302 and shaft 304 may then be positioned relative to coronary anatomy by manipulation of the catheter 308, etc. Once the mitral valve implant 301 has been arranged relative to coronary anatomy, the mitral valve implant 301 may be fully deployed from the catheter 308. Alternatively, the mitral valve implant 301 may be fully deployed from the catheter 308. Following deployment, the mitral valve implant 301 may be manipulated to achieve a position and/or arrangement relative to coronary anatomy. Consistent with such an embodiment, the anchor 306 of the mitral valve implant 301 may be engaged with coronary tissue before, during, or after complete deployment of the mitral valve implant 301. Various other techniques and methods may also suitably be employed.
At least a portion of the mitral valve implant 301 may be collapsible and/or reducible in volume to facilitate percutaneous and/or transluminal delivery. In such a manner, the valve body 302 of the mitral valve implant 301 may be a collapsible member, which can be reduced in volume and/or reduced in maximum diameter during delivery to the heart and/or during placement and/or attachment of the anchor to native coronary tissue. After delivery to the heart, the valve body 302 may be expanded, inflated, and/or otherwise increased in volume or size.
Accordingly, the mitral valve implant 301 may be delivered to an implantation site via a smaller diameter catheter, and/or via smaller vessels, than would otherwise be required.
With reference to FIG. 11, according to one embodiment, the mitral valve implant may include an inflatable valve body 402. An inflatable valve body 402 may include an at least partially deformable body 404 defining at least one cavity 406. The body 404 may further define an opening 408 capable of receiving at least a portion of a shaft 410 therein.
Additionally or alternatively, the body may include one or more features for coupling the body to a shaft.
The at least partially deformable valve body 404 may be collapsed to a reduced size, which may, for example, allow the valve body 404 to be loaded into a catheter delivery system.
Such a catheter delivery system may be suitable for transluminal delivery of a mitral valve implant, including the inflatable valve body 402, to the heart. In addition to being collapsed, the valve body 402 may be deformed to facilitate loading into a catheter delivery system. For example, the valve body 402 may be collapsed and may be rolled and/or folded to a generally cylindrical shape, allowing the valve body 402 to be loaded in a catheter having a circular lumen.
A collapsed and/or rolled or folded valve body 402 may be inflated, restoring the valve body 402 to expanded configuration. For example, a collapsed and/or rolled or folded valve body 402 may be inflated and restored to an expanded configuration once the mitral valve implant has been delivered to the heart and deployed from a catheter delivery system. Inflating the valve body 402 may be carried out by introducing a fluid, such as saline, into the at least one cavity 406. In addition to a liquid, such as saline, the valve body may be inflated with a setting or curable fluid. The setting or curable fluid may set and/or be cured to a solid and/or semi-solid state within the cavity of the valve body. An example of such a material may be a thermoset polymer resin, a gel material, such as silicone gel, etc.
According to one embodiment, after delivery to the heart and deployment from the catheter delivery system, the at least one cavity may be filled with a fluid by injecting the fluid into the cavity via a filling tube extending through and/or with the catheter delivery system.
Other filling methods and systems may also suitably be employed herein. In an inflated state, the valve body may be shaped and/or configured for use in connection with a translating and/or a stationary mitral valve implant, as described previously.
According to another embodiment, shown in FIG. 12, the valve body 502 may be expandable. An embodiment of an expandable valve body 502 suitable for use in connection with a mitral valve implant herein may include a recoverably deformable shell 504 defining the shape of the valve body 502. Similar to previous embodiments, the valve body 502 may include an opening 506 for receiving a shaft 508 of a mitral valve implant at least partially therein.
According to one embodiment, the opening 506 may provide a passage extending through the valve body 502. Additionally and/or alternatively, the valve body may include features for coupling the valve body to the shaft.
The recoverably deformable shell 504 may be deformable, for example, to permit the valve body 502 to be collapsed, folded, rolled, etc., for loading into a catheter delivery system, and/or to facilitate delivery of a mitral valve implant including the valve body 502 to an implantation site, e.g., within the heart. The recoverably deformable shell 504 may further be recoverable, allowing the valve body 502 to return to the expanded configuration from a deformed configuration.
Consistent with one aspect, the deformable she11504 may include a resiliently deformable material, such as an elastomer, which may be elastically deformed under stress. The deformable she11504 may elastically recover when the stress is removed. In such an embodiment, the deformable she11504 may, for example, be deformed from an expanded configuration to a collapsed condition and loaded into a catheter delivery system. After delivery to an implant site, the deformable shell 504 may be deployed from the catheter delivery system, thereby removing the deforming stress from the valve body 502. Once the deforming stress is removed, the deformable shell 504 may resiliently recover back to the expanded configuration.
In a related embodiment, the deformable shell may include a shape memory material, such as Nitinol, etc. The deformable shell may be collapsed and/or deformed to facilitate delivery of the implant to the desired site, e.g., via a transluminal and/or a surgical procedure.
The deformable shell may subsequently be recovered to an expanded configuration. In an embodiment using a thermally activated shape memory material, recovery of the shape memory deformable shell may be accomplished by heating the deformable shell to, or above, an activation temperature. Heat for activating the shape memory material may be provided by the body temperature of the subject receiving the mitral valve implant, and/or from an external source, e.g., via the catheter, etc.
An embodiment of mitral valve implant may include an expandable/recoverable valve body including a cellular material. The cellular material may be, for example, a deformable and/or compressible expanded material, such as a polymeric foam material. The valve body may be deformed, compressed, and/or collapsed to a reduced volume configuration, at least in part, by compressing or deforming the cellular material. The mitral valve implant may be transported to an implant site as disclosed. When the implant is deployed from the delivery system the valve body may recover to a generally original volume and/or configuration. Recovery of the valve body may include recovery and/or expansion of the cellular material.
In another related embodiment, depicted in FIG. 13, an expandable valve body 602 may include deformable and/or flexible outer she11604. The outer shell 604 may be supported in an expanded configuration by one or more recoverably deformable supports. In the embodiment of FIG. 13, the recoverably deformable support may be provided as a resiliently deformable rib 606. The deformable she11604 may be a resiliently deformable material and/or may be a flexible material. The resiliently deformable rib 606 and/or the deformable she11604 may be deformed, e.g., to collapse the valve body 602 from an expanded configuration, under a deforming stress.
As discussed with reference to other embodiments, collapsing the valve body 602 may facilitate transport to an mitral valve implant, for example, using a catheter delivery system. When the deforming stress is released, e.g., by deploying the valve body 602 from a delivery system, the recoverably deformable rib 606 and/or the deformable outer shell 604 may resiliently recover to restore the valve body 602 to an expanded condition. While only a single rib is depicted in the illustrated embodiment, the valve body may alternatively include a plurality of recoverably deformable ribs.
In various embodiments, the recoverably deformable supports may be configured as ribs, generally having a transverse orientation relative to the axis of the valve body, such as depicted in FIG. 13. In additional and/or alternative embodiments, a valve body 702 may include a deformable and/or flexible outer shell (not shown) covering and/or supported by recoverably deformable supports in the form of resiliently deformable stringers 704. As depicted in FIG. 14, the recoverably deformable stringers 704 may be generally oriented along the longitudinal axis of the valve body 702. In a further embodiment, the recoverably deformable supports may be configured as a lattice, scaffolding, etc. supporting a deformable and/or flexible outer shell of the valve body. Further embodiments may include combinations ribs and stringers.
Various other configurations of recoverably deformable supports may also suitably be employed.
In addition to resiliently recoverable shell, supports, etc., a mitral valve implant may include a valve body having an outer shell and/or having supports which may be controllably recoverable. For example, an outer shell and/or one or more supports of a mitral valve implant valve body may be formed from a shape memory material. Such materials may include shape memory metal alloys, shape memory polymers, etc. Consistent with such embodiments, the valve body may be collapsed and/or otherwise deformed from an expanded configuration. The collapsed and/or deformed valve body may maintain the collapsed and/or deformed configuration after the initial deforming stress is released. The valve body may subsequently be returned to the expanded and/or operable configuration, for example, by heating the valve body above an activation temperature of the shape memory material, which may induce recovery of the shape memory material to a pre-deformed shape. The activation temperature inducing recovery of the deformed valve body may be provided by the body temperature of the patient receiving the mitral valve implant. Alternatively, heat for activating recovery of the shape memory material may be provided by a heating element coupled to the valve body and/or a heating element delivered through a catheter. In other embodiments, activating heat may be provided by irradiating the shape memory material, e.g., with microwaves, IR
light, etc.
Another embodiment of a valve body 800, suitable for use in a mitral valve implant, is shown in FIG. 15. The valve body 800 may include first and second enlarged portions 802, 804 joined by a narrow region 806. In one such embodiment, the valve body may have a generally hourglass shape, as shown. The valve body 800 may be positioned relative to a mitral valve such that the first enlarged portion 802 may be disposed at least partially within the left atrium and the second enlarged portion may be disposed at least partially within the left ventricle. The valve body may be maintained in position relative to the coronary anatomy by an anchor and/or a shaft consistent with any preceding embodiment. Additionally, the valve body 800 may be a collapsible and/or expandable member consistent with any previously discussed embodiment.
Referring now to FIGS. 16A-16B, another embodiment of a mitral valve implant 900 is shown. Mitral valve implant 900 generally includes expandable member 902, shaft 904 and anchor 906. Expandable member 902 may be an inflatable member capable of expanding or contracting in order to conform with portions of the mitral valve. For example, expandable member 902 may expand until the exterior surface "e" of expandable member 902 approaches or conforms with one or more of the leaflets and/or cusps of the mitral valve.
Expandable member 902 may include a central portion 903, proximal end 905 and distal end 907. Ends 905, 907 of expandable member 902 may each be tapered and configured to form an opening capable of allowing shaft 904 to pass therethrough. This opening could be configured into a variety of different geometries including, but not limited to, circular, square, oval, etc. Ends 905, 907 may be configured to form a seal around shaft 904 in order to prevent the inflation medium from escaping before, during or after inflation. In some embodiments, proximal end 905 may be connected to a connecting member 908, which may include a valve portion (not shown) for insufflation/deflation. Proximal and distal ends 905, 907 may be expandable, however, in other embodiments proximal and distal ends 905, 907 may be constructed out of a rigid non-expandable material, leaving an expandable central portion 903.
Expandable member 902 may include central portion 903 as well as proximal and distal ends 905, 907. Central portion 903 may be monolithically formed with proximal and distal ends 905 and 907. Alternatively, central portion 903 may be configured to connect with proximal and distal ends 905 and 907 to form a seal. Expandable member 902 may be constructed out of a variety of different materials. Some expanding materials may include polymeric materials, elastomeric materials, rubber, latex, chloroprene, nylon fabrics, or any other suitable materials.
The exterior surface "e" of expandable member 902 may be smooth or rough and may include ridges or irregular contours capable of receiving portions of the mitral valve. In some embodiments, the exterior surface of expandable member 902 may include a fabric material capable of contacting and interacting with the leaflets of the mitral valve.
In some embodiments, central portion 903 may also include a coating, which may provide a non-stick surface. Central portion 903 may include other materials as well including, but not limited to, fabric materials, microfibers, nanomaterials, etc. Ends 905 and 907 may include similar materials.
In some embodiments, shaft 904 may be securely attached to the proximal and/or distal ends 905, 907 of expandable member 902. This attachment may be achieved using welding or any other suitable connection. Shaft 904 may also include anchor portion 906, which may be constructed in a variety of different configurations such as the helical arrangement described hereinabove. In some embodiments, expandable member 902 may be slidably movable about shaft 904. For example, expandable member 902 may slide about shaft 904 in a distal direction until reaching anchor portion 906. Similarly, expandable member 902 may be configured to slide in a proximal direction before coming into contact with connecting member 908. Stops, such as those described herein, may be employed to limit the axial movement of expandable member 902. In some embodiments, expandable member 902 may be adjusted and placed in different positions along shaft 904. For example, shaft 904 may include ridges or other adjustment mechanisms capable of forming an interface with ends 905 and 907 of expandable member 902. Using this type of arrangement, expandable member 902 may be adjusted to a number of different positions along shaft 904. Shaft 904 may be constructed out of a variety of different materials and may be rigid or flexible in nature. Moreover, shaft 904 may be hollow and may further include a variety of apertures capable of transporting an inflation medium to the interior "i" of expandable member 902. In some embodiments, the hollow shaft may receive an inflation medium from a hose affixed to connecting member 908. Upon entering the hollow shaft this medium may travel in a distal direction until reaching the plurality of apertures, at which point the medium may exit shaft 904 and insufflate the interior of expandable member 902. Shaft 904 may be entirely solid or entirely hollow or may include both solid and hollow portions. For example, shaft 904 may be hollow until the distal end 907 of expandable member 902 is reached and solid thereafter.
Connecting member 908 may establish a connection between expandable member 902 and a conduit (not shown) such as a hose or other device. This conduit may be connected to an inflation device in order to provide the necessary expansion to expandable member 902.
Expandable member 902 may include pressure sensors and may be capable of indicating the current pressure within the interior of expandable member 902. This information may be provided to the inflation device using telemetry or any other suitable techniques.
Expandable member 902 may be configured to receive a variety of different substances through connecting member 908. These substances may include, but are not limited to, liquids, gases (e.g., air, helium, hydrogen, nitrous oxide), gels, flouro visible materials, etc. Connecting member 908 may be affixed to the conduit and/or expandable member 902 using a variety of different arrangements, including but not limited to, compression fittings, ferrules, screw-fittings, snap-fittings, press-fittings, welding, threaded rod, etc. In some embodiments connecting member 908 may be monolithically formed with expandable member 902 and/or shaft 904.
Connecting member may further include a valve portion (not shown) that may be used to inflate or deflate expandable member 902. Valve portion (not shown) may include but is not limited to, ball-check valves, swing-check valves, clapper valves, stop-check valves and lift-check valves.
Expandable member 902 may be detachably removable from shaft 904 using a variety of different techniques, including, but not limited to, by disconnecting connecting member 908 from shaft 904 and/or expandable member 902. For example, if expandable member 902 is defective or in need of replacement, connecting member 908 may be disconnected and expandable member 902 may be removed and a new valve body may be used as a replacement.
Referring now to FIG. 16B, a cross-sectional view of mitral valve implant 900 is shown.
FIG. 16B shows expandable member 902 having internal layer "i" and external layer "e".
Expandable member 902 defines an internal chamber "c" configured to receive an inflation medium. Internal layer "i" and external layer "e" may each be constructed out of a resiliently deformable material. For example, internal layer "i" may be constructed out of an open or closed cell foam material, which may be compressed into a catheter and delivered to the operative site.
In some embodiments, internal layer "i" may be constructed out of shape memory alloy (e.g., copper-zinc-aluminum, copper-aluminum-nickel, nickel-titanium, etc.) forming a scaffold or strut matrix. Materials having shape memory properties may provide a layer that is capable of moving with expandable member 902 from an initial position to an expanded position and back.
The resiliently deformable properties of expandable member 902 allow exterior layer "e" and interior layer "i" to at least partially conform with the shape of the leaflets of the heart valve.
Interior layer "i" defines an opening or chamber within expandable member 902.
This chamber "c" may be configured to receive an inflation medium from shaft 904. External layer "e" may be disposed over the internal layer "i" as shown in FIG. 16B. External layer "e"
may be constructed out of a variety of different materials, including, but not limited to, expanded PolyTetraFluoroEthylene (EPTFE) and high silicone content, polyurethane copolymers such as ElasteonTM available from AorTech International PLC of the United Kingdom.
Referring now to Figures 17a and 17b mitral valve implant 900 is shown in an initial and expanded position respectively. Implant 900 may be secured to an area of the heart using anchor portion 906. Expandable member 902 may be adjusted axially along shaft 904 until the desired position is reached (e.g., adjusting the depth of anchor portion 906, adjusting via shaft adjustment mechanisms, etc.). At this point an inflation medium may be fed into valve body 902 via a hose or other conduit 950. This medium may cause expandable member 902 to expand away from shaft 904 and possibly create contact with the leaflets of the mitral valve as shown in Figure 17b.
In addition to the circular configuration shown in Figures 16-17, expandable member 902 may include a number of different shapes and configurations. Some possible geometries may include, but are not limited to, round, elliptical, pear shaped, self-shaping, hourglass shaped, etc.
Expandable member 902 may include a uniform or irregular diameter along its length "1". For example, the width "w" of expandable member 902 may increase or decrease along its length "1"
traveling between proximal end 905 and distal end 907.
Referring now to Figure 18, a mitral valve implant 1000 including a pear-shaped expandable member 1002 is shown. Implant 1000 may include shaft 1004, anchor portion 1006, and proximal and distal ends 1005, 1007 as described above. In this embodiment, expandable member 1002 is shown having a tapered configuration, increasing in diameter from a more narrow geometry to a wider geometry as the distal end 1007 of expandable member 1002 is approached. Of course, this tapered configuration could be altered and may include varying degrees of curvature. For example, the diameter of expandable member 1002 could decrease in diameter as the distal end 1007 of expandable member 1002 is approached.
Figure 19 shows another embodiment of a mitral valve implant 1100 having a heart-shaped or partially heart-shaped configuration. Implant 1100 may be positioned between the leaflets of the mitral valve and insufflated until the desired position is obtained. Of course, other shapes and configurations are also envisioned. For example, an additional embodiment of an implant 1200 is depicted in Figure 20. Implant 1200 may include a plurality of ridges "r" or grooves capable of abutting with the mitral valve. The exterior surface of expandable member 1202 may include a variety of different surfaces and surface geometries. For example, ridges, grooves, and/or convex or concave indentations may be provided upon the exterior surface of expandable member 1202 to interact with the leaflets of the mitral valve.
These variations upon the exterior surface may be used in accordance with any of the embodiments described herein.
Figure 21 shows yet another embodiment of a mitral valve implant 1300. Mitral valve implant 1300 may include expandable member 1302, shaft 1304 and anchor portion 1306.
Implant 1300 includes expanded proximal and distal ends 1305 and 1307 that connect via narrow central portion 1303. In some embodiments, implant 1300 may be positioned to allow for any portion of expandable member 1302 to contact the mitral valve. The expansion characteristics of central portion 1303, proximal end 1305 and distal end 1307 may be consistent or irregular. For example, in some embodiments, ends 1305 and 1307 may expand at substantially the same rate while central portion 1303 expands at a slower rate. This may be achieved using different construction methods for each section and/or constructing each section out of different materials or by using varying degrees of thickness. Of course, altering the design and/or material properties of the expandable member may be performed using any or all of the embodiments described herein.
Referring now to Figures 22A and 22B, an additional embodiment of a mitral valve implant 1400 is shown. Mitral valve implant 1400 may include expandable member 1402, shaft 1404 and anchor portion 1406. Figure 22A depicts implant 1400 in an "at rest"
position.
Implant 1400 may further include a plurality of protrusions 1420 connected via linkage portion 1422. Aspects of linkage portion 1422 and protrusions 1420 may be configured to receive an inflation medium and to expand in a transverse direction from shaft 1404.
Protrusions 1420 may be expandable and may be further configured to receive gels or other substances, which may be capable of hardening after entering expandable member 1402. Some substances may maintain a self-shaping property, which may allow portions of expandable member 1402 to conform to the leaflets of the mitral valve. Figure 22B shows an embodiment of implant 1400 in an expanded position. Implant 1400 may be expanded until protrusions 1420 and/or linkage portion 1422 contact the leaflets of the mitral valve.
Figure 23 provides an additional embodiment of mitral valve implant 1500 having a detachable expandable member 1502. Implant 1500 includes connector portion 1508, which may be a screw-fit, snap-fit or any other suitable configuration. In this embodiment, connector portion 1508 may be detached from expandable member 1502 and/or shaft 1504, allowing for the removal and/or replacement of expandable member 1502. In some embodiments, connector portion 1508 and expandable member 1502 may be permanently affixed. If so, the connector portion 1508 and expandable member 1502 may both need to be removed from shaft 1504.
Shaft 1504 and anchor portion 1506 may remain in an anchored position while the existing expandable member is removed and replaced.
In some embodiments, the valve implant described herein may be used as a sizing mechanism in order to determine the approximate distance between the leaflets of the mitral valve. In other words, once the approximate size of the opening is determined via the valve implant a mold having a similar construction may be created and inserted in order to provide a more permanent device.
In some embodiments, the expandable member may be filled with a fluoro-visible material, which may provide the surgeon with improved visibility during the placement of implant. The implant may be positioned in an uninflated state and subsequently inflated after it has been placed in the appropriate position, possibly between the leaflets of the mitral valve.
The fluoro-visible material may remain within the expandable member or may be removed and replaced with an alternative substance.
The implant herein has been disclosed above in the context of a mitral valve implant. An implant consistent with the present disclosure may also suitably be employed in other applications, e.g., as an implant associated with one of the other valves of the heart, etc. The present disclosure should not, therefore, be construed as being limited to use for reducing and/or preventing regurgitation of the mitral valve.
The terms valve body and expandable member, as described herein, may be used interchangeably to refer to a portion of the valve implant that may conform with at least a portion of at least one leaflet of a heart valve. While the depicted embodiments including expandable and/or recoverably deformable valve bodies have generally been shown configured as a expandable member consistent with a stationary valve implant, an expandable and/or recoverably deformable expandable member may be configured for use as part of a valve implant including a translating valve body. Similarly, while the valve implant embodiments including an expandable expandable member have been discussed in connection with transluminal and/or percutaneous delivery systems and/or procedures, such embodiments may also suitably be employed in connection with surgical delivery systems and/or methods. Additionally, other features and aspects of the various embodiments may also suitably be combined and/or modified consistent with the present disclosure. The disclosure herein should not, therefore, be limited to any particular disclosed embodiment, and should be given full scope of the appended claims.
Claims (22)
1. A heart valve implant comprising:
a shaft;
an anchor disposed on one end of the shaft, the anchor configured to engage tissue; and an expandable member disposed over at least part of the shaft, the expandable member comprising a resiliently deformable internal layer and a resiliently deformable external layer disposed over the internal layer, the expandable member defining a chamber and being configured to receive an inflation medium in the chamber to expand the expandable member, the expandable member further configured to deform upon contact with at least a portion of at least one leaflet of a heart valve to at least partially conform to the shape of the leaflet.
a shaft;
an anchor disposed on one end of the shaft, the anchor configured to engage tissue; and an expandable member disposed over at least part of the shaft, the expandable member comprising a resiliently deformable internal layer and a resiliently deformable external layer disposed over the internal layer, the expandable member defining a chamber and being configured to receive an inflation medium in the chamber to expand the expandable member, the expandable member further configured to deform upon contact with at least a portion of at least one leaflet of a heart valve to at least partially conform to the shape of the leaflet.
2. The heart valve implant according to claim 1, wherein the resiliently deformable internal layer is a scaffold structure comprising a matrix of interconnected individual members.
3. The heart valve implant according to claim 2, wherein the scaffold structure includes a shape memory alloy.
4. The heart valve implant according to claim 1, wherein the resiliently deformable internal layer includes a foam material.
5. The heart valve implant according to claim 1, wherein the resiliently external layer is constructed out of a high silicone content, polyurethane copolymer.
6. The heart valve implant according to claim 1, wherein the inflation medium is selected from the group comprising at least one of a gas, liquid, gel, and/or flouro-visible material.
7. The heart valve implant according to claim 1, wherein the expandable member is further configured to receive a hardening gel.
8. The heart valve implant according to claim 1, wherein the expandable member is controllably expandable to expand the member to a selectable cross-sectional diameter.
9. The heart valve implant according to claim 1, wherein the expandable member is expanded to a shape selected from the group consisting of round, pear-shaped, elliptical, hourglass-shaped, oval and heart-shaped.
10. The heart valve implant according to claim 1, wherein the expandable member is removably attached to the shaft.
11. The heart valve implant according to claim 1, wherein the expandable member is slidably coupled to the shaft.
12. The heart valve implant according to claim 1, wherein the expandable member is configured to determine the distance between a first leaflet and a second leaflet of a heart valve.
13. The heart valve implant according to claim 1, further comprising a connecting member removably coupled to the shaft.
14. The heart valve implant according to claim 1, wherein the external layer includes a plurality of ridges.
15. The heart valve implant according to claim 1, wherein the shaft includes an adjustment mechanism configured to permit the axial movement of the expandable member along the shaft.
16. A method comprising:
providing a heart valve implant comprising a shaft, an anchor operatively connected to the shaft and an expandable member operatively connected to the shaft;
at least partially collapsing the heart valve implant;
percutaneously inserting the at least partially collapsed heart valve implant into a heart;
securing the at least partially collapsed heart valve implant within the heart; and expanding the collapsed heart valve implant to interact with at least a portion of at least one cusp of a heart valve to at least partially restrict a flow of blood through the heart valve in a closed position.
providing a heart valve implant comprising a shaft, an anchor operatively connected to the shaft and an expandable member operatively connected to the shaft;
at least partially collapsing the heart valve implant;
percutaneously inserting the at least partially collapsed heart valve implant into a heart;
securing the at least partially collapsed heart valve implant within the heart; and expanding the collapsed heart valve implant to interact with at least a portion of at least one cusp of a heart valve to at least partially restrict a flow of blood through the heart valve in a closed position.
17. The method according to claim 16, further comprising determining the size of a heart valve.
18. The method according to claim 16, wherein percutaneously inserting is performed via a catheter.
19. The method according to claim 16, further comprising detaching the expandable member from the shaft and removing the expandable member via a catheter.
20. The method according to claim 16, further comprising insufflating the expandable member via a connecting member.
21. The method according to claim 16, further comprising deflating the expandable member via a connecting member.
22. The method according to claim 16, further comprising adjustably positioning the expandable member about the shaft.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/748,121 US8449606B2 (en) | 2005-10-26 | 2007-05-14 | Balloon mitral spacer |
US11/748,121 | 2007-05-14 | ||
PCT/US2008/063560 WO2008141322A1 (en) | 2007-05-14 | 2008-05-14 | Balloon mitral spacer |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2697358A1 true CA2697358A1 (en) | 2008-11-20 |
CA2697358C CA2697358C (en) | 2016-04-05 |
Family
ID=40002909
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2697358A Active CA2697358C (en) | 2007-05-14 | 2008-05-14 | Balloon mitral spacer |
Country Status (5)
Country | Link |
---|---|
US (3) | US8449606B2 (en) |
EP (1) | EP2150206B1 (en) |
BR (1) | BRPI0810270A2 (en) |
CA (1) | CA2697358C (en) |
WO (1) | WO2008141322A1 (en) |
Families Citing this family (306)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0850607A1 (en) | 1996-12-31 | 1998-07-01 | Cordis Corporation | Valve prosthesis for implantation in body channels |
US6454799B1 (en) | 2000-04-06 | 2002-09-24 | Edwards Lifesciences Corporation | Minimally-invasive heart valves and methods of use |
US7678151B2 (en) | 2000-05-01 | 2010-03-16 | Ek Steven W | System and method for joint resurface repair |
US6520964B2 (en) | 2000-05-01 | 2003-02-18 | Std Manufacturing, Inc. | System and method for joint resurface repair |
US7163541B2 (en) | 2002-12-03 | 2007-01-16 | Arthrosurface Incorporated | Tibial resurfacing system |
US6610067B2 (en) | 2000-05-01 | 2003-08-26 | Arthrosurface, Incorporated | System and method for joint resurface repair |
US8177841B2 (en) | 2000-05-01 | 2012-05-15 | Arthrosurface Inc. | System and method for joint resurface repair |
US7713305B2 (en) * | 2000-05-01 | 2010-05-11 | Arthrosurface, Inc. | Articular surface implant |
US7896885B2 (en) | 2002-12-03 | 2011-03-01 | Arthrosurface Inc. | Retrograde delivery of resurfacing devices |
US6733525B2 (en) | 2001-03-23 | 2004-05-11 | Edwards Lifesciences Corporation | Rolled minimally-invasive heart valves and methods of use |
US6814713B2 (en) * | 2001-04-25 | 2004-11-09 | A-Med Systems, Inc. | Systems for performing minimally invasive cardiac medical procedures |
US6893460B2 (en) | 2001-10-11 | 2005-05-17 | Percutaneous Valve Technologies Inc. | Implantable prosthetic valve |
US7901408B2 (en) | 2002-12-03 | 2011-03-08 | Arthrosurface, Inc. | System and method for retrograde procedure |
US8388624B2 (en) | 2003-02-24 | 2013-03-05 | Arthrosurface Incorporated | Trochlear resurfacing system and method |
US20050075725A1 (en) | 2003-10-02 | 2005-04-07 | Rowe Stanton J. | Implantable prosthetic valve with non-laminar flow |
EP1845890A4 (en) | 2003-11-20 | 2010-06-09 | Arthrosurface Inc | System and method for retrograde procedure |
US7951163B2 (en) * | 2003-11-20 | 2011-05-31 | Arthrosurface, Inc. | Retrograde excision system and apparatus |
US8377118B2 (en) | 2004-05-05 | 2013-02-19 | Direct Flow Medical, Inc. | Unstented heart valve with formed in place support structure |
JP2008504107A (en) | 2004-06-28 | 2008-02-14 | アースロサーフィス・インコーポレーテッド | Joint surface replacement system |
AU2004324043A1 (en) | 2004-10-02 | 2006-04-20 | Christoph Hans Huber | Methods and devices for repair or replacement of heart valves or adjacent tissue without the need for full cardiopulmonary support |
US7828853B2 (en) | 2004-11-22 | 2010-11-09 | Arthrosurface, Inc. | Articular surface implant and delivery system |
WO2006064490A1 (en) * | 2004-12-15 | 2006-06-22 | Mednua Limited | A medical device suitable for use in treatment of a valve |
EP3967269A3 (en) | 2005-02-07 | 2022-07-13 | Evalve, Inc. | Systems and devices for cardiac valve repair |
US8470028B2 (en) | 2005-02-07 | 2013-06-25 | Evalve, Inc. | Methods, systems and devices for cardiac valve repair |
JP5119148B2 (en) | 2005-06-07 | 2013-01-16 | ダイレクト フロウ メディカル、 インク. | Stentless aortic valve replacement with high radial strength |
US7780723B2 (en) | 2005-06-13 | 2010-08-24 | Edwards Lifesciences Corporation | Heart valve delivery system |
US20070179608A1 (en) * | 2005-07-29 | 2007-08-02 | Arthrosurface, Inc. | System and method for articular surface repair |
US8167932B2 (en) | 2005-10-18 | 2012-05-01 | Edwards Lifesciences Corporation | Heart valve delivery system with valve catheter |
US8092525B2 (en) | 2005-10-26 | 2012-01-10 | Cardiosolutions, Inc. | Heart valve implant |
US8778017B2 (en) | 2005-10-26 | 2014-07-15 | Cardiosolutions, Inc. | Safety for mitral valve implant |
US7785366B2 (en) | 2005-10-26 | 2010-08-31 | Maurer Christopher W | Mitral spacer |
US8449606B2 (en) | 2005-10-26 | 2013-05-28 | Cardiosolutions, Inc. | Balloon mitral spacer |
US8852270B2 (en) * | 2007-11-15 | 2014-10-07 | Cardiosolutions, Inc. | Implant delivery system and method |
US8216302B2 (en) | 2005-10-26 | 2012-07-10 | Cardiosolutions, Inc. | Implant delivery and deployment system and method |
US9259317B2 (en) | 2008-06-13 | 2016-02-16 | Cardiosolutions, Inc. | System and method for implanting a heart implant |
US8932348B2 (en) | 2006-05-18 | 2015-01-13 | Edwards Lifesciences Corporation | Device and method for improving heart valve function |
EP3241525B2 (en) | 2006-06-01 | 2022-06-08 | Edwards Lifesciences Corporation | Prosthetic insert for use with a mitral valve |
US9408607B2 (en) | 2009-07-02 | 2016-08-09 | Edwards Lifesciences Cardiaq Llc | Surgical implant devices and methods for their manufacture and use |
AU2007281553B2 (en) | 2006-07-31 | 2013-09-19 | Edwards Lifesciences Cardiaq Llc | Sealable endovascular implants and methods for their use |
US9585743B2 (en) | 2006-07-31 | 2017-03-07 | Edwards Lifesciences Cardiaq Llc | Surgical implant devices and methods for their manufacture and use |
CA2998123C (en) | 2006-09-08 | 2021-03-02 | Edwards Lifesciences Corporation | Integrated heart valve delivery system |
US8133213B2 (en) | 2006-10-19 | 2012-03-13 | Direct Flow Medical, Inc. | Catheter guidance through a calcified aortic valve |
US7935144B2 (en) | 2006-10-19 | 2011-05-03 | Direct Flow Medical, Inc. | Profile reduction of valve implant |
EP2136717B1 (en) | 2006-12-11 | 2013-10-16 | Arthrosurface Incorporated | Retrograde resection apparatus |
US8236045B2 (en) | 2006-12-22 | 2012-08-07 | Edwards Lifesciences Corporation | Implantable prosthetic valve assembly and method of making the same |
US8480730B2 (en) | 2007-05-14 | 2013-07-09 | Cardiosolutions, Inc. | Solid construct mitral spacer |
US9566178B2 (en) | 2010-06-24 | 2017-02-14 | Edwards Lifesciences Cardiaq Llc | Actively controllable stent, stent graft, heart valve and method of controlling same |
AU2008288796B2 (en) | 2007-08-23 | 2014-03-20 | Dfm, Llc | Cardiovascular prosthetic valve |
US8597347B2 (en) * | 2007-11-15 | 2013-12-03 | Cardiosolutions, Inc. | Heart regurgitation method and apparatus |
EP4079261A1 (en) | 2007-12-14 | 2022-10-26 | Edwards Lifesciences Corporation | Leaflet attachment frame for a prosthetic valve |
CA2961051C (en) | 2008-02-29 | 2020-01-14 | Edwards Lifesciences Corporation | Expandable member for deploying a prosthetic device |
EP2262448A4 (en) | 2008-03-03 | 2014-03-26 | Arthrosurface Inc | Bone resurfacing system and method |
US9061119B2 (en) | 2008-05-09 | 2015-06-23 | Edwards Lifesciences Corporation | Low profile delivery system for transcatheter heart valve |
WO2009149462A2 (en) | 2008-06-06 | 2009-12-10 | Edwards Lifesciences Corporation | Low profile transcatheter heart valve |
US8591460B2 (en) | 2008-06-13 | 2013-11-26 | Cardiosolutions, Inc. | Steerable catheter and dilator and system and method for implanting a heart implant |
US8323335B2 (en) | 2008-06-20 | 2012-12-04 | Edwards Lifesciences Corporation | Retaining mechanisms for prosthetic valves and methods for using |
US8652202B2 (en) | 2008-08-22 | 2014-02-18 | Edwards Lifesciences Corporation | Prosthetic heart valve and delivery apparatus |
WO2016154393A1 (en) | 2009-04-17 | 2016-09-29 | Arthrosurface Incorporated | Glenoid repair system and methods of use thereof |
WO2010121246A1 (en) | 2009-04-17 | 2010-10-21 | Arthrosurface Incorporated | Glenoid resurfacing system and method |
US9662126B2 (en) | 2009-04-17 | 2017-05-30 | Arthrosurface Incorporated | Glenoid resurfacing system and method |
US8475522B2 (en) | 2009-07-14 | 2013-07-02 | Edwards Lifesciences Corporation | Transapical delivery system for heart valves |
EP3042615A1 (en) | 2009-09-15 | 2016-07-13 | Evalve, Inc. | Methods, systems and devices for cardiac valve repair |
US8449599B2 (en) | 2009-12-04 | 2013-05-28 | Edwards Lifesciences Corporation | Prosthetic valve for replacing mitral valve |
US10058323B2 (en) | 2010-01-22 | 2018-08-28 | 4 Tech Inc. | Tricuspid valve repair using tension |
US9307980B2 (en) | 2010-01-22 | 2016-04-12 | 4Tech Inc. | Tricuspid valve repair using tension |
US8475525B2 (en) | 2010-01-22 | 2013-07-02 | 4Tech Inc. | Tricuspid valve repair using tension |
CA2792048A1 (en) | 2010-03-05 | 2011-09-09 | Arthrosurface Incorporated | Tibial resurfacing system and method |
WO2011109813A2 (en) | 2010-03-05 | 2011-09-09 | Edwards Lifesciences Corporation | Retaining mechanisms for prosthetic valves |
US8795354B2 (en) | 2010-03-05 | 2014-08-05 | Edwards Lifesciences Corporation | Low-profile heart valve and delivery system |
US8579964B2 (en) | 2010-05-05 | 2013-11-12 | Neovasc Inc. | Transcatheter mitral valve prosthesis |
US9526483B2 (en) | 2010-07-15 | 2016-12-27 | Medtronic Vascular Galway | Apical closure system |
US8657872B2 (en) | 2010-07-19 | 2014-02-25 | Jacques Seguin | Cardiac valve repair system and methods of use |
WO2012012761A2 (en) | 2010-07-23 | 2012-01-26 | Edwards Lifesciences Corporation | Retaining mechanisms for prosthetic valves |
DE202011111128U1 (en) | 2010-10-05 | 2020-05-27 | Edwards Lifesciences Corporation | Prosthetic heart valve |
US9005279B2 (en) * | 2010-11-12 | 2015-04-14 | Shlomo Gabbay | Beating heart buttress and implantation method to prevent prolapse of a heart valve |
CA2822381C (en) | 2010-12-23 | 2019-04-02 | Foundry Newco Xii, Inc. | System for mitral valve repair and replacement |
US8845717B2 (en) | 2011-01-28 | 2014-09-30 | Middle Park Medical, Inc. | Coaptation enhancement implant, system, and method |
US8888843B2 (en) | 2011-01-28 | 2014-11-18 | Middle Peak Medical, Inc. | Device, system, and method for transcatheter treatment of valve regurgitation |
US9155619B2 (en) | 2011-02-25 | 2015-10-13 | Edwards Lifesciences Corporation | Prosthetic heart valve delivery apparatus |
US9066716B2 (en) | 2011-03-30 | 2015-06-30 | Arthrosurface Incorporated | Suture coil and suture sheath for tissue repair |
US9554897B2 (en) | 2011-04-28 | 2017-01-31 | Neovasc Tiara Inc. | Methods and apparatus for engaging a valve prosthesis with tissue |
US9308087B2 (en) | 2011-04-28 | 2016-04-12 | Neovasc Tiara Inc. | Sequentially deployed transcatheter mitral valve prosthesis |
US9289282B2 (en) | 2011-05-31 | 2016-03-22 | Edwards Lifesciences Corporation | System and method for treating valve insufficiency or vessel dilatation |
CN107496054B (en) | 2011-06-21 | 2020-03-03 | 托尔福公司 | Prosthetic heart valve devices and related systems and methods |
WO2013016618A2 (en) | 2011-07-27 | 2013-01-31 | The Cleveland Clinic Foundation | Apparatus, system, and method for treating a regurgitant heart valve |
US9119716B2 (en) | 2011-07-27 | 2015-09-01 | Edwards Lifesciences Corporation | Delivery systems for prosthetic heart valve |
US10799360B2 (en) | 2011-07-27 | 2020-10-13 | The Cleveland Clinic Foundation | Systems and methods for treating a regurgitant heart valve |
US9510948B2 (en) | 2011-09-09 | 2016-12-06 | Emory University | Systems, devices and methods for repair of heart valve lesions |
EP3943047B1 (en) | 2011-10-19 | 2023-08-30 | Twelve, Inc. | Device for heart valve replacement |
US9763780B2 (en) | 2011-10-19 | 2017-09-19 | Twelve, Inc. | Devices, systems and methods for heart valve replacement |
US9655722B2 (en) | 2011-10-19 | 2017-05-23 | Twelve, Inc. | Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods |
CN111000663B (en) | 2011-10-19 | 2022-04-15 | 托尔福公司 | Prosthetic heart valve devices, prosthetic mitral valves, and related systems and methods |
US11202704B2 (en) | 2011-10-19 | 2021-12-21 | Twelve, Inc. | Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods |
US9039757B2 (en) | 2011-10-19 | 2015-05-26 | Twelve, Inc. | Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods |
US9827093B2 (en) | 2011-10-21 | 2017-11-28 | Edwards Lifesciences Cardiaq Llc | Actively controllable stent, stent graft, heart valve and method of controlling same |
CA3201836A1 (en) | 2011-12-09 | 2013-06-13 | Edwards Lifesciences Corporation | Prosthetic heart valve having improved commissure supports |
US8652145B2 (en) | 2011-12-14 | 2014-02-18 | Edwards Lifesciences Corporation | System and method for crimping a prosthetic valve |
US9078747B2 (en) | 2011-12-21 | 2015-07-14 | Edwards Lifesciences Corporation | Anchoring device for replacing or repairing a heart valve |
WO2013096746A1 (en) | 2011-12-22 | 2013-06-27 | Arthrosurface Incorporated | System and method for bone fixation |
JP6049761B2 (en) | 2012-01-31 | 2016-12-21 | マイトラル・ヴァルヴ・テクノロジーズ・エス・アー・エール・エル | Mitral valve docking device, system, and method |
CA2865013C (en) | 2012-02-22 | 2020-12-15 | Syntheon Cardiology, Llc | Actively controllable stent, stent graft, heart valve and method of controlling same |
US9579198B2 (en) | 2012-03-01 | 2017-02-28 | Twelve, Inc. | Hydraulic delivery systems for prosthetic heart valve devices and associated methods |
US9414823B2 (en) | 2012-04-25 | 2016-08-16 | Medtronic Ventor Technologies Ltd. | Hole-closure device |
WO2013173618A2 (en) | 2012-05-16 | 2013-11-21 | Edwards Lifesciences Corporation | Systems and methods for placing a coapting member between valvular leaflets |
US9474605B2 (en) | 2012-05-16 | 2016-10-25 | Edwards Lifesciences Corporation | Devices and methods for reducing cardiac valve regurgitation |
US9345573B2 (en) | 2012-05-30 | 2016-05-24 | Neovasc Tiara Inc. | Methods and apparatus for loading a prosthesis onto a delivery system |
US8961594B2 (en) | 2012-05-31 | 2015-02-24 | 4Tech Inc. | Heart valve repair system |
WO2014008126A1 (en) | 2012-07-03 | 2014-01-09 | Arthrosurface Incorporated | System and method for joint resurfacing and repair |
WO2014022124A1 (en) | 2012-07-28 | 2014-02-06 | Tendyne Holdings, Inc. | Improved multi-component designs for heart valve retrieval device, sealing structures and stent assembly |
US9675454B2 (en) * | 2012-07-30 | 2017-06-13 | Tendyne Holdings, Inc. | Delivery systems and methods for transcatheter prosthetic valves |
ES2931210T3 (en) | 2012-11-21 | 2022-12-27 | Edwards Lifesciences Corp | Retention Mechanisms for Prosthetic Heart Valves |
EP2943132B1 (en) | 2013-01-09 | 2018-03-28 | 4Tech Inc. | Soft tissue anchors |
US9168129B2 (en) | 2013-02-12 | 2015-10-27 | Edwards Lifesciences Corporation | Artificial heart valve with scalloped frame design |
WO2014141239A1 (en) | 2013-03-14 | 2014-09-18 | 4Tech Inc. | Stent with tether interface |
US9232998B2 (en) | 2013-03-15 | 2016-01-12 | Cardiosolutions Inc. | Trans-apical implant systems, implants and methods |
US9289297B2 (en) * | 2013-03-15 | 2016-03-22 | Cardiosolutions, Inc. | Mitral valve spacer and system and method for implanting the same |
US9572665B2 (en) | 2013-04-04 | 2017-02-21 | Neovasc Tiara Inc. | Methods and apparatus for delivering a prosthetic valve to a beating heart |
US9492200B2 (en) | 2013-04-16 | 2016-11-15 | Arthrosurface Incorporated | Suture system and method |
US9763781B2 (en) * | 2013-05-07 | 2017-09-19 | George Kramer | Inflatable transcatheter intracardiac devices and methods for treating incompetent atrioventricular valves |
CN108294846A (en) | 2013-05-20 | 2018-07-20 | 托尔福公司 | Implantable cardiac valve device, mitral valve repair device and related system and method |
CA2908342C (en) | 2013-05-20 | 2021-11-30 | Edwards Lifesciences Corporation | Prosthetic heart valve delivery apparatus |
AU2014277902A1 (en) * | 2013-06-14 | 2016-02-04 | Cardiosolutions, Inc. | Mitral valve spacer and system and method for implanting the same |
SG10202103500PA (en) | 2013-08-12 | 2021-05-28 | Mitral Valve Tech Sarl | Apparatus and methods for implanting a replacement heart valve |
JP6328242B2 (en) | 2013-08-14 | 2018-05-23 | マイトラル・ヴァルヴ・テクノロジーズ・エス・アー・エール・エル | System for heart valve replacement |
US10052198B2 (en) | 2013-08-14 | 2018-08-21 | Mitral Valve Technologies Sarl | Coiled anchor for supporting prosthetic heart valve, prosthetic heart valve, and deployment device |
US10195028B2 (en) | 2013-09-10 | 2019-02-05 | Edwards Lifesciences Corporation | Magnetic retaining mechanisms for prosthetic valves |
US10166098B2 (en) | 2013-10-25 | 2019-01-01 | Middle Peak Medical, Inc. | Systems and methods for transcatheter treatment of valve regurgitation |
US10052095B2 (en) | 2013-10-30 | 2018-08-21 | 4Tech Inc. | Multiple anchoring-point tension system |
US10039643B2 (en) | 2013-10-30 | 2018-08-07 | 4Tech Inc. | Multiple anchoring-point tension system |
US10022114B2 (en) | 2013-10-30 | 2018-07-17 | 4Tech Inc. | Percutaneous tether locking |
CR20160240A (en) | 2013-11-11 | 2016-08-04 | Edwards Lifesciences Cardiaq Llc | SYSTEMS AND METHODS FOR THE MANUFACTURE OF THE FRAME OF A CANNULA |
US9622863B2 (en) | 2013-11-22 | 2017-04-18 | Edwards Lifesciences Corporation | Aortic insufficiency repair device and method |
DE102013224283A1 (en) * | 2013-11-27 | 2015-06-11 | Deutsches Herzzentrum Berlin | Device for transcutaneous implantation of epicardial pacemaker electrodes |
US10098734B2 (en) | 2013-12-05 | 2018-10-16 | Edwards Lifesciences Corporation | Prosthetic heart valve and delivery apparatus |
US9901444B2 (en) | 2013-12-17 | 2018-02-27 | Edwards Lifesciences Corporation | Inverted valve structure |
PT3107500T (en) | 2014-02-18 | 2021-12-24 | Edwards Lifesciences Corp | Flexible commissure frame |
EP3107498B1 (en) | 2014-02-21 | 2020-09-30 | Mitral Valve Technologies Sàrl | Prosthetic mitral valve with anchoring device |
US10624748B2 (en) | 2014-03-07 | 2020-04-21 | Arthrosurface Incorporated | System and method for repairing articular surfaces |
US9931219B2 (en) | 2014-03-07 | 2018-04-03 | Arthrosurface Incorporated | Implant and anchor assembly |
US11607319B2 (en) | 2014-03-07 | 2023-03-21 | Arthrosurface Incorporated | System and method for repairing articular surfaces |
US10154904B2 (en) | 2014-04-28 | 2018-12-18 | Edwards Lifesciences Corporation | Intravascular introducer devices |
US10195025B2 (en) | 2014-05-12 | 2019-02-05 | Edwards Lifesciences Corporation | Prosthetic heart valve |
CA2958061A1 (en) | 2014-06-18 | 2015-12-23 | Middle Peak Medical, Inc. | Mitral valve implants for the treatment of valvular regurgitation |
CN106573129B (en) | 2014-06-19 | 2019-09-24 | 4科技有限公司 | Heart tissue is tightened |
EP3160396B1 (en) | 2014-06-24 | 2022-03-23 | Polares Medical Inc. | Systems for anchoring an implant |
US10016272B2 (en) | 2014-09-12 | 2018-07-10 | Mitral Valve Technologies Sarl | Mitral repair and replacement devices and methods |
WO2016050751A1 (en) | 2014-09-29 | 2016-04-07 | Martin Quinn | A heart valve treatment device and method |
US20160144156A1 (en) | 2014-11-20 | 2016-05-26 | Edwards Lifesciences Corporation | Inflatable device with etched modifications |
US9907547B2 (en) | 2014-12-02 | 2018-03-06 | 4Tech Inc. | Off-center tissue anchors |
WO2016090308A1 (en) | 2014-12-04 | 2016-06-09 | Edwards Lifesciences Corporation | Percutaneous clip for repairing a heart valve |
CR20170245A (en) | 2014-12-05 | 2017-09-14 | Edwards Lifesciences Corp | DIRIGIBLE CATETER WITH TRACTION CABLE |
US10383726B2 (en) | 2015-01-13 | 2019-08-20 | George Kramer | Implantable transcatheter intracardiac devices and methods for treating incompetent atrioventricular valves |
US10231834B2 (en) | 2015-02-09 | 2019-03-19 | Edwards Lifesciences Corporation | Low profile transseptal catheter and implant system for minimally invasive valve procedure |
US10105226B2 (en) | 2015-02-10 | 2018-10-23 | Edwards Lifesciences Corporation | Offset cardiac leaflet coaptation element |
US10039637B2 (en) | 2015-02-11 | 2018-08-07 | Edwards Lifesciences Corporation | Heart valve docking devices and implanting methods |
US10327896B2 (en) | 2015-04-10 | 2019-06-25 | Edwards Lifesciences Corporation | Expandable sheath with elastomeric cross sectional portions |
US10792471B2 (en) | 2015-04-10 | 2020-10-06 | Edwards Lifesciences Corporation | Expandable sheath |
US10232564B2 (en) | 2015-04-29 | 2019-03-19 | Edwards Lifesciences Corporation | Laminated sealing member for prosthetic heart valve |
DE102015005933A1 (en) * | 2015-05-12 | 2016-11-17 | Coramaze Technologies Gmbh | Implantable device for improving or eliminating heart valve insufficiency |
DE102015005934A1 (en) * | 2015-05-12 | 2016-11-17 | Coramaze Technologies Gmbh | Implantable device for improving or eliminating heart valve insufficiency |
EP3294219B1 (en) | 2015-05-14 | 2020-05-13 | Edwards Lifesciences Corporation | Heart valve sealing devices and delivery devices therefor |
US9974650B2 (en) | 2015-07-14 | 2018-05-22 | Edwards Lifesciences Corporation | Prosthetic heart valve |
US10179046B2 (en) | 2015-08-14 | 2019-01-15 | Edwards Lifesciences Corporation | Gripping and pushing device for medical instrument |
US11026788B2 (en) | 2015-08-20 | 2021-06-08 | Edwards Lifesciences Corporation | Loader and retriever for transcatheter heart valve, and methods of crimping transcatheter heart valve |
EP3337428A1 (en) | 2015-08-21 | 2018-06-27 | Twelve Inc. | Implantable heart valve devices, mitral valve repair devices and associated systems and methods |
US10588744B2 (en) | 2015-09-04 | 2020-03-17 | Edwards Lifesciences Corporation | Delivery system for prosthetic heart valve |
US10314703B2 (en) | 2015-09-21 | 2019-06-11 | Edwards Lifesciences Corporation | Cylindrical implant and balloon |
US10350067B2 (en) | 2015-10-26 | 2019-07-16 | Edwards Lifesciences Corporation | Implant delivery capsule |
US11259920B2 (en) | 2015-11-03 | 2022-03-01 | Edwards Lifesciences Corporation | Adapter for prosthesis delivery device and methods of use |
US9592121B1 (en) | 2015-11-06 | 2017-03-14 | Middle Peak Medical, Inc. | Device, system, and method for transcatheter treatment of valvular regurgitation |
US10321996B2 (en) | 2015-11-11 | 2019-06-18 | Edwards Lifesciences Corporation | Prosthetic valve delivery apparatus having clutch mechanism |
US11033387B2 (en) | 2015-11-23 | 2021-06-15 | Edwards Lifesciences Corporation | Methods for controlled heart valve delivery |
US10265169B2 (en) | 2015-11-23 | 2019-04-23 | Edwards Lifesciences Corporation | Apparatus for controlled heart valve delivery |
US10583007B2 (en) | 2015-12-02 | 2020-03-10 | Edwards Lifesciences Corporation | Suture deployment of prosthetic heart valve |
US10357351B2 (en) | 2015-12-04 | 2019-07-23 | Edwards Lifesciences Corporation | Storage assembly for prosthetic valve |
US11008676B2 (en) | 2015-12-16 | 2021-05-18 | Edwards Lifesciences Corporation | Textured woven fabric for use in implantable bioprostheses |
US10433952B2 (en) | 2016-01-29 | 2019-10-08 | Neovasc Tiara Inc. | Prosthetic valve for avoiding obstruction of outflow |
US10363130B2 (en) | 2016-02-05 | 2019-07-30 | Edwards Lifesciences Corporation | Devices and systems for docking a heart valve |
US10179043B2 (en) | 2016-02-12 | 2019-01-15 | Edwards Lifesciences Corporation | Prosthetic heart valve having multi-level sealing member |
ES2964770T3 (en) | 2016-02-29 | 2024-04-09 | Coramaze Tech Gmbh | cardiac implant |
WO2017151566A1 (en) | 2016-03-01 | 2017-09-08 | Spence Paul A | System, devices and methods for anchoring and/or sealing a heart valve prosthesis |
US10779941B2 (en) | 2016-03-08 | 2020-09-22 | Edwards Lifesciences Corporation | Delivery cylinder for prosthetic implant |
US10799677B2 (en) | 2016-03-21 | 2020-10-13 | Edwards Lifesciences Corporation | Multi-direction steerable handles for steering catheters |
US10799675B2 (en) | 2016-03-21 | 2020-10-13 | Edwards Lifesciences Corporation | Cam controlled multi-direction steerable handles |
US10835714B2 (en) | 2016-03-21 | 2020-11-17 | Edwards Lifesciences Corporation | Multi-direction steerable handles for steering catheters |
US10799676B2 (en) | 2016-03-21 | 2020-10-13 | Edwards Lifesciences Corporation | Multi-direction steerable handles for steering catheters |
US11219746B2 (en) | 2016-03-21 | 2022-01-11 | Edwards Lifesciences Corporation | Multi-direction steerable handles for steering catheters |
CA3216740A1 (en) | 2016-03-24 | 2017-09-28 | Edwards Lifesciences Corporation | Delivery system for prosthetic heart valve |
US10159569B2 (en) | 2016-04-12 | 2018-12-25 | Lars Erickson | Minimally invasive atrio-ventricular valve treatment by chordae adjustment |
US10799358B2 (en) | 2016-04-12 | 2020-10-13 | Lars Erickson | Catheter system for selectively manipulating and connecting cardiac tissues |
WO2017189276A1 (en) | 2016-04-29 | 2017-11-02 | Medtronic Vascular Inc. | Prosthetic heart valve devices with tethered anchors and associated systems and methods |
US20170325949A1 (en) * | 2016-05-13 | 2017-11-16 | Cardiosolutions, Inc. | Heart Valve Implant And Methods For Delivering And Implanting Same |
US10973638B2 (en) | 2016-07-07 | 2021-04-13 | Edwards Lifesciences Corporation | Device and method for treating vascular insufficiency |
US10856981B2 (en) | 2016-07-08 | 2020-12-08 | Edwards Lifesciences Corporation | Expandable sheath and methods of using the same |
US10828150B2 (en) | 2016-07-08 | 2020-11-10 | Edwards Lifesciences Corporation | Docking station for heart valve prosthesis |
US11096781B2 (en) | 2016-08-01 | 2021-08-24 | Edwards Lifesciences Corporation | Prosthetic heart valve |
CN106419970B (en) * | 2016-08-03 | 2018-12-25 | 上海甲悦医疗器械有限公司 | A kind of supporting rod type bicuspid valve air bag closure plate occluder and method for implantation being implanted into through the apex of the heart |
CR20190069A (en) | 2016-08-26 | 2019-05-14 | Edwards Lifesciences Corp | Heart valve docking coils and systems |
US10722359B2 (en) | 2016-08-26 | 2020-07-28 | Edwards Lifesciences Corporation | Heart valve docking devices and systems |
US10357361B2 (en) | 2016-09-15 | 2019-07-23 | Edwards Lifesciences Corporation | Heart valve pinch devices and delivery systems |
WO2018050202A1 (en) * | 2016-09-16 | 2018-03-22 | Coramaze Technologies Gmbh | Heart implant |
WO2018050203A1 (en) * | 2016-09-16 | 2018-03-22 | Coramaze Technologies Gmbh | Heart implant |
US10575944B2 (en) | 2016-09-22 | 2020-03-03 | Edwards Lifesciences Corporation | Prosthetic heart valve with reduced stitching |
US10653862B2 (en) | 2016-11-07 | 2020-05-19 | Edwards Lifesciences Corporation | Apparatus for the introduction and manipulation of multiple telescoping catheters |
US10973631B2 (en) | 2016-11-17 | 2021-04-13 | Edwards Lifesciences Corporation | Crimping accessory device for a prosthetic valve |
US10463484B2 (en) | 2016-11-17 | 2019-11-05 | Edwards Lifesciences Corporation | Prosthetic heart valve having leaflet inflow below frame |
AU2017361296B2 (en) | 2016-11-21 | 2022-09-29 | Neovasc Tiara Inc. | Methods and systems for rapid retraction of a transcatheter heart valve delivery system |
US10603165B2 (en) | 2016-12-06 | 2020-03-31 | Edwards Lifesciences Corporation | Mechanically expanding heart valve and delivery apparatus therefor |
HUE061376T2 (en) | 2016-12-16 | 2023-06-28 | Edwards Lifesciences Corp | Deployment systems and tools for delivering an anchoring device for a prosthetic valve |
US10813749B2 (en) | 2016-12-20 | 2020-10-27 | Edwards Lifesciences Corporation | Docking device made with 3D woven fabric |
EP3906893A1 (en) | 2016-12-20 | 2021-11-10 | Edwards Lifesciences Corporation | Systems and mechanisms for deploying a docking device for a replacement heart valve |
US10905554B2 (en) | 2017-01-05 | 2021-02-02 | Edwards Lifesciences Corporation | Heart valve coaptation device |
US11013600B2 (en) | 2017-01-23 | 2021-05-25 | Edwards Lifesciences Corporation | Covered prosthetic heart valve |
US11185406B2 (en) | 2017-01-23 | 2021-11-30 | Edwards Lifesciences Corporation | Covered prosthetic heart valve |
US11654023B2 (en) | 2017-01-23 | 2023-05-23 | Edwards Lifesciences Corporation | Covered prosthetic heart valve |
USD867595S1 (en) | 2017-02-01 | 2019-11-19 | Edwards Lifesciences Corporation | Stent |
US10653524B2 (en) | 2017-03-13 | 2020-05-19 | Polares Medical Inc. | Device, system, and method for transcatheter treatment of valvular regurgitation |
CN110913801B (en) | 2017-03-13 | 2022-04-15 | 宝来瑞斯医疗有限公司 | Coaptation assistance element for treating an adverse coaptation of a heart valve of a heart and system for delivering the same |
US10478303B2 (en) | 2017-03-13 | 2019-11-19 | Polares Medical Inc. | Device, system, and method for transcatheter treatment of valvular regurgitation |
DE102017002974A1 (en) | 2017-03-28 | 2018-10-04 | Immanuel Diakonie Gmbh | Heart valve implant, suitable for use in minimally invasive surgery for the repair of a heart valve and / or a heart valve beating on the beating heart |
US10702378B2 (en) | 2017-04-18 | 2020-07-07 | Twelve, Inc. | Prosthetic heart valve device and associated systems and methods |
IL269799B2 (en) | 2017-04-18 | 2023-10-01 | Edwards Lifesciences Corp | Heart valve sealing devices and delivery devices therefor |
US10575950B2 (en) | 2017-04-18 | 2020-03-03 | Twelve, Inc. | Hydraulic systems for delivering prosthetic heart valve devices and associated methods |
US11224511B2 (en) | 2017-04-18 | 2022-01-18 | Edwards Lifesciences Corporation | Heart valve sealing devices and delivery devices therefor |
US10433961B2 (en) | 2017-04-18 | 2019-10-08 | Twelve, Inc. | Delivery systems with tethers for prosthetic heart valve devices and associated methods |
US10973634B2 (en) | 2017-04-26 | 2021-04-13 | Edwards Lifesciences Corporation | Delivery apparatus for a prosthetic heart valve |
US10799312B2 (en) | 2017-04-28 | 2020-10-13 | Edwards Lifesciences Corporation | Medical device stabilizing apparatus and method of use |
US10959846B2 (en) | 2017-05-10 | 2021-03-30 | Edwards Lifesciences Corporation | Mitral valve spacer device |
US10792151B2 (en) | 2017-05-11 | 2020-10-06 | Twelve, Inc. | Delivery systems for delivering prosthetic heart valve devices and associated methods |
US10842619B2 (en) | 2017-05-12 | 2020-11-24 | Edwards Lifesciences Corporation | Prosthetic heart valve docking assembly |
US11135056B2 (en) | 2017-05-15 | 2021-10-05 | Edwards Lifesciences Corporation | Devices and methods of commissure formation for prosthetic heart valve |
EP3630013A4 (en) | 2017-05-22 | 2020-06-17 | Edwards Lifesciences Corporation | Valve anchor and installation method |
US20210401571A9 (en) | 2017-05-31 | 2021-12-30 | Edwards Lifesciences Corporation | Sealing member for prosthetic heart valve |
US10646338B2 (en) | 2017-06-02 | 2020-05-12 | Twelve, Inc. | Delivery systems with telescoping capsules for deploying prosthetic heart valve devices and associated methods |
US11026785B2 (en) | 2017-06-05 | 2021-06-08 | Edwards Lifesciences Corporation | Mechanically expandable heart valve |
US10869759B2 (en) | 2017-06-05 | 2020-12-22 | Edwards Lifesciences Corporation | Mechanically expandable heart valve |
US10709591B2 (en) | 2017-06-06 | 2020-07-14 | Twelve, Inc. | Crimping device and method for loading stents and prosthetic heart valves |
US10639152B2 (en) | 2017-06-21 | 2020-05-05 | Edwards Lifesciences Corporation | Expandable sheath and methods of using the same |
CN110891526A (en) | 2017-06-30 | 2020-03-17 | 爱德华兹生命科学公司 | Locking and releasing mechanism for transcatheter implantable devices |
CA3068313A1 (en) | 2017-06-30 | 2019-01-03 | Edwards Lifesciences Corporation | Docking stations for transcatheter valves |
US10729541B2 (en) | 2017-07-06 | 2020-08-04 | Twelve, Inc. | Prosthetic heart valve devices and associated systems and methods |
US10786352B2 (en) | 2017-07-06 | 2020-09-29 | Twelve, Inc. | Prosthetic heart valve devices and associated systems and methods |
JP7134229B2 (en) * | 2017-07-06 | 2022-09-09 | ラグビア バスデ, | Tissue grasping device and related method |
WO2019011391A1 (en) * | 2017-07-10 | 2019-01-17 | Coramaze Technologies Gmbh | Heart implant |
US10857334B2 (en) | 2017-07-12 | 2020-12-08 | Edwards Lifesciences Corporation | Reduced operation force inflator |
US10918473B2 (en) | 2017-07-18 | 2021-02-16 | Edwards Lifesciences Corporation | Transcatheter heart valve storage container and crimping mechanism |
US11160663B2 (en) | 2017-08-04 | 2021-11-02 | Arthrosurface Incorporated | Multicomponent articular surface implant |
KR102617878B1 (en) | 2017-08-11 | 2023-12-22 | 에드워즈 라이프사이언시스 코포레이션 | Sealing elements for artificial heart valves |
US11083575B2 (en) | 2017-08-14 | 2021-08-10 | Edwards Lifesciences Corporation | Heart valve frame design with non-uniform struts |
US10932903B2 (en) | 2017-08-15 | 2021-03-02 | Edwards Lifesciences Corporation | Skirt assembly for implantable prosthetic valve |
US10898319B2 (en) | 2017-08-17 | 2021-01-26 | Edwards Lifesciences Corporation | Sealing member for prosthetic heart valve |
US10973628B2 (en) | 2017-08-18 | 2021-04-13 | Edwards Lifesciences Corporation | Pericardial sealing member for prosthetic heart valve |
US10722353B2 (en) | 2017-08-21 | 2020-07-28 | Edwards Lifesciences Corporation | Sealing member for prosthetic heart valve |
USD890333S1 (en) | 2017-08-21 | 2020-07-14 | Edwards Lifesciences Corporation | Heart valve docking coil |
US10806573B2 (en) | 2017-08-22 | 2020-10-20 | Edwards Lifesciences Corporation | Gear drive mechanism for heart valve delivery apparatus |
US10856984B2 (en) | 2017-08-25 | 2020-12-08 | Neovasc Tiara Inc. | Sequentially deployed transcatheter mitral valve prosthesis |
US11141145B2 (en) | 2017-08-25 | 2021-10-12 | Edwards Lifesciences Corporation | Devices and methods for securing a tissue anchor |
US11051939B2 (en) | 2017-08-31 | 2021-07-06 | Edwards Lifesciences Corporation | Active introducer sheath system |
US10973629B2 (en) | 2017-09-06 | 2021-04-13 | Edwards Lifesciences Corporation | Sealing member for prosthetic heart valve |
US11051940B2 (en) | 2017-09-07 | 2021-07-06 | Edwards Lifesciences Corporation | Prosthetic spacer device for heart valve |
US11147667B2 (en) | 2017-09-08 | 2021-10-19 | Edwards Lifesciences Corporation | Sealing member for prosthetic heart valve |
US11065117B2 (en) | 2017-09-08 | 2021-07-20 | Edwards Lifesciences Corporation | Axisymmetric adjustable device for treating mitral regurgitation |
US11040174B2 (en) | 2017-09-19 | 2021-06-22 | Edwards Lifesciences Corporation | Multi-direction steerable handles for steering catheters |
CN115177404A (en) | 2017-10-18 | 2022-10-14 | 爱德华兹生命科学公司 | Catheter assembly |
US11207499B2 (en) | 2017-10-20 | 2021-12-28 | Edwards Lifesciences Corporation | Steerable catheter |
US10799350B2 (en) | 2018-01-05 | 2020-10-13 | Edwards Lifesciences Corporation | Percutaneous implant retrieval connector and method |
US10159570B1 (en) | 2018-01-09 | 2018-12-25 | Edwards Lifesciences Corporation | Native valve repair devices and procedures |
US10231837B1 (en) | 2018-01-09 | 2019-03-19 | Edwards Lifesciences Corporation | Native valve repair devices and procedures |
US10245144B1 (en) | 2018-01-09 | 2019-04-02 | Edwards Lifesciences Corporation | Native valve repair devices and procedures |
US10238493B1 (en) | 2018-01-09 | 2019-03-26 | Edwards Lifesciences Corporation | Native valve repair devices and procedures |
US10123873B1 (en) | 2018-01-09 | 2018-11-13 | Edwards Lifesciences Corporation | Native valve repair devices and procedures |
US10973639B2 (en) | 2018-01-09 | 2021-04-13 | Edwards Lifesciences Corporation | Native valve repair devices and procedures |
CN111655198A (en) | 2018-01-09 | 2020-09-11 | 爱德华兹生命科学公司 | Native valve repair devices and procedures |
US10507109B2 (en) | 2018-01-09 | 2019-12-17 | Edwards Lifesciences Corporation | Native valve repair devices and procedures |
US10136993B1 (en) | 2018-01-09 | 2018-11-27 | Edwards Lifesciences Corporation | Native valve repair devices and procedures |
US10111751B1 (en) | 2018-01-09 | 2018-10-30 | Edwards Lifesciences Corporation | Native valve repair devices and procedures |
US10076415B1 (en) | 2018-01-09 | 2018-09-18 | Edwards Lifesciences Corporation | Native valve repair devices and procedures |
WO2019144121A1 (en) | 2018-01-22 | 2019-07-25 | Edwards Lifesciences Corporation | Heart shape preserving anchor |
JP7300455B2 (en) | 2018-02-09 | 2023-06-29 | ザ プロボースト,フェローズ,ファンデーション スカラーズ,アンド ジ アザー メンバーズ オブ ボード,オブ ザ カレッジ オブ ザ ホーリー アンド アンディバイデッド トリニティ オブ クイーン エリザベス ニア ダブリン | heart valve therapy device |
US11285003B2 (en) | 2018-03-20 | 2022-03-29 | Medtronic Vascular, Inc. | Prolapse prevention device and methods of use thereof |
US11026791B2 (en) | 2018-03-20 | 2021-06-08 | Medtronic Vascular, Inc. | Flexible canopy valve repair systems and methods of use |
US11389297B2 (en) | 2018-04-12 | 2022-07-19 | Edwards Lifesciences Corporation | Mitral valve spacer device |
US11207181B2 (en) | 2018-04-18 | 2021-12-28 | Edwards Lifesciences Corporation | Heart valve sealing devices and delivery devices therefor |
US11318011B2 (en) | 2018-04-27 | 2022-05-03 | Edwards Lifesciences Corporation | Mechanically expandable heart valve with leaflet clamps |
US11007061B2 (en) | 2018-05-24 | 2021-05-18 | Edwards Lifesciences Corporation | Adjustable percutaneous heart valve repair system |
US11844914B2 (en) | 2018-06-05 | 2023-12-19 | Edwards Lifesciences Corporation | Removable volume indicator for syringe |
FR3085835B1 (en) | 2018-09-13 | 2020-08-28 | Univ Compiegne Tech | HEART VALVE IMPLANT |
US10945844B2 (en) | 2018-10-10 | 2021-03-16 | Edwards Lifesciences Corporation | Heart valve sealing devices and delivery devices therefor |
KR20210082188A (en) | 2018-10-19 | 2021-07-02 | 에드워즈 라이프사이언시스 코포레이션 | Artificial heart valve with non-cylindrical frame |
US11779728B2 (en) | 2018-11-01 | 2023-10-10 | Edwards Lifesciences Corporation | Introducer sheath with expandable introducer |
CA3118599A1 (en) | 2018-11-08 | 2020-05-14 | Neovasc Tiara Inc. | Ventricular deployment of a transcatheter mitral valve prosthesis |
US11452604B2 (en) * | 2018-11-27 | 2022-09-27 | Boston Scientific Scimed, Inc. | Systems and methods for treating regurgitating cardiac valves |
US20220054267A1 (en) * | 2019-01-14 | 2022-02-24 | Valfix Medical Ltd. | Percutaneous Valve Implants |
CR20210427A (en) | 2019-02-14 | 2022-03-30 | Edwards Lifesciences Corp | Heart valve sealing devices and delivery devices therefor |
GB2616360B (en) | 2019-03-12 | 2023-11-29 | Arthrosurface Inc | Humeral and glenoid articular surface implant systems and methods |
CN113873973B (en) | 2019-03-26 | 2023-12-22 | 爱德华兹生命科学公司 | prosthetic heart valve |
US11602429B2 (en) | 2019-04-01 | 2023-03-14 | Neovasc Tiara Inc. | Controllably deployable prosthetic valve |
AU2020271896B2 (en) | 2019-04-10 | 2022-10-13 | Neovasc Tiara Inc. | Prosthetic valve with natural blood flow |
EP3972673A4 (en) | 2019-05-20 | 2023-06-07 | Neovasc Tiara Inc. | Introducer with hemostasis mechanism |
WO2020257643A1 (en) | 2019-06-20 | 2020-12-24 | Neovasc Tiara Inc. | Low profile prosthetic mitral valve |
CA3148739A1 (en) | 2019-08-05 | 2021-02-11 | Croivalve Ltd. | Apparatus and methods for treating a defective cardiac valve |
EP4054484A4 (en) * | 2019-11-07 | 2023-12-13 | Primo Medical Group, Inc. | Systems, apparatus and methods to repair operation of a heart valve |
BR112023002487A2 (en) | 2020-08-24 | 2023-05-02 | Edwards Lifesciences Corp | BALLOON COVER FOR A DISTRIBUTION APPLIANCE FOR AN EXPANDABLE PROSTHETIC HEART VALVE |
JP2023540067A (en) | 2020-08-31 | 2023-09-21 | エドワーズ ライフサイエンシーズ コーポレイション | Systems and methods for crimping and device preparation |
US11464634B2 (en) | 2020-12-16 | 2022-10-11 | Polares Medical Inc. | Device, system, and method for transcatheter treatment of valvular regurgitation with secondary anchors |
US11759321B2 (en) | 2021-06-25 | 2023-09-19 | Polares Medical Inc. | Device, system, and method for transcatheter treatment of valvular regurgitation |
Family Cites Families (182)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2549731A (en) | 1944-12-18 | 1951-04-17 | Vincent E Wattley | Flexible test prod |
US2625967A (en) | 1949-12-19 | 1953-01-20 | Illinois Tool Works | Screw-holding and screw-driving tool |
US3197788A (en) | 1962-04-23 | 1965-08-03 | Inst Of Medical Sciences | Prosthetic valve for cardiac surgery |
US3445916A (en) | 1967-04-19 | 1969-05-27 | Rudolf R Schulte | Method for making an anatomical check valve |
US3551913A (en) | 1968-04-02 | 1971-01-05 | Donald P Shiley | Heart valve prosthesis with guard structure |
GB1268484A (en) | 1968-06-28 | 1972-03-29 | Brian John Bellhouse | Improvements relating to non-return valves particularly as prosthetics |
US3589392A (en) | 1969-05-05 | 1971-06-29 | Louis C Meyer | Split leaflet check valve for cardiac surgery and the like |
US3586029A (en) | 1969-06-16 | 1971-06-22 | Aero Flow Dynamics Inc | Apparatus for automatically controlling fluid flow according to predetermined volumetric proportions |
US3671979A (en) | 1969-09-23 | 1972-06-27 | Univ Utah | Catheter mounted artificial heart valve for implanting in close proximity to a defective natural heart valve |
GB1264472A (en) | 1969-09-25 | 1972-02-23 | ||
US3689942A (en) | 1969-11-28 | 1972-09-12 | Richard K Rapp | Prosthetic heart valve |
US3739402A (en) | 1970-10-15 | 1973-06-19 | Cutter Lab | Bicuspid fascia lata valve |
US3714671A (en) | 1970-11-30 | 1973-02-06 | Cutter Lab | Tissue-type heart valve with a graft support ring or stent |
US3737919A (en) | 1971-03-16 | 1973-06-12 | Univ Minnesota | Pivoted disc-type heart valve |
US4291420A (en) | 1973-11-09 | 1981-09-29 | Medac Gesellschaft Fur Klinische Spezialpraparate Mbh | Artificial heart valve |
US3983581A (en) | 1975-01-20 | 1976-10-05 | William W. Angell | Heart valve stent |
AR206762A1 (en) | 1976-01-01 | 1976-08-13 | Pisanu A | LOW PROFILE BIOPROTHESIS DERIVED FROM PORCINE HETEROLOGICAL AORTIC VALVE |
US4084268A (en) | 1976-04-22 | 1978-04-18 | Shiley Laboratories, Incorporated | Prosthetic tissue heart valve |
US4297749A (en) | 1977-04-25 | 1981-11-03 | Albany International Corp. | Heart valve prosthesis |
AR221872A1 (en) | 1979-03-16 | 1981-03-31 | Liotta Domingo S | IMPROVEMENTS IN IMPANTABLE HEART VALVES |
EP0125393B1 (en) | 1980-11-03 | 1987-12-09 | Shiley Incorporated | Prosthetic heart valve |
US4439185A (en) * | 1981-10-21 | 1984-03-27 | Advanced Cardiovascular Systems, Inc. | Inflating and deflating device for vascular dilating catheter assembly |
US4535757A (en) | 1982-03-12 | 1985-08-20 | Webster Wilton W Jr | Autoinflatable catheter |
US4597767A (en) | 1982-12-15 | 1986-07-01 | Andrew Lenkei | Split leaflet heart valve |
US4865030A (en) | 1987-01-21 | 1989-09-12 | American Medical Systems, Inc. | Apparatus for removal of objects from body passages |
US4960424A (en) | 1988-06-30 | 1990-10-02 | Grooters Ronald K | Method of replacing a defective atrio-ventricular valve with a total atrio-ventricular valve bioprosthesis |
US5002067A (en) | 1989-08-23 | 1991-03-26 | Medtronic, Inc. | Medical electrical lead employing improved penetrating electrode |
US5665100A (en) | 1989-12-05 | 1997-09-09 | Yoon; Inbae | Multifunctional instrument with interchangeable operating units for performing endoscopic procedures |
US5797958A (en) | 1989-12-05 | 1998-08-25 | Yoon; Inbae | Endoscopic grasping instrument with scissors |
DK124690D0 (en) | 1990-05-18 | 1990-05-18 | Henning Rud Andersen | FAT PROTECTION FOR IMPLEMENTATION IN THE BODY FOR REPLACEMENT OF NATURAL FLEET AND CATS FOR USE IN IMPLEMENTING A SUCH FAT PROTECTION |
US5411552A (en) | 1990-05-18 | 1995-05-02 | Andersen; Henning R. | Valve prothesis for implantation in the body and a catheter for implanting such valve prothesis |
GB9012716D0 (en) | 1990-06-07 | 1990-08-01 | Frater Robert W M | Mitral heart valve replacements |
US5397351A (en) | 1991-05-13 | 1995-03-14 | Pavcnik; Dusan | Prosthetic valve for percutaneous insertion |
US5217484A (en) | 1991-06-07 | 1993-06-08 | Marks Michael P | Retractable-wire catheter device and method |
US5370685A (en) | 1991-07-16 | 1994-12-06 | Stanford Surgical Technologies, Inc. | Endovascular aortic valve replacement |
US5261916A (en) | 1991-12-12 | 1993-11-16 | Target Therapeutics | Detachable pusher-vasoocclusive coil assembly with interlocking ball and keyway coupling |
EP0791333B1 (en) | 1991-12-12 | 1999-12-01 | Target Therapeutics, Inc. | Detachable pusher-vasoocclusive coil assembly with interlocking coupling |
US5222973A (en) | 1992-03-09 | 1993-06-29 | Sharpe Endosurgical Corporation | Endoscopic grasping tool surgical instrument |
US5318589A (en) | 1992-04-15 | 1994-06-07 | Microsurge, Inc. | Surgical instrument for endoscopic surgery |
US5308357A (en) | 1992-08-21 | 1994-05-03 | Microsurge, Inc. | Handle mechanism for manual instruments |
US5350397A (en) | 1992-11-13 | 1994-09-27 | Target Therapeutics, Inc. | Axially detachable embolic coil assembly |
US6283127B1 (en) | 1992-12-03 | 2001-09-04 | Wesley D. Sterman | Devices and methods for intracardiac procedures |
US5462527A (en) | 1993-06-29 | 1995-10-31 | C.R. Bard, Inc. | Actuator for use with steerable catheter |
US5638827A (en) | 1994-02-01 | 1997-06-17 | Symbiosis Corporation | Super-elastic flexible jaws assembly for an endoscopic multiple sample bioptome |
US5611800A (en) | 1994-02-15 | 1997-03-18 | Alphatec Manufacturing, Inc. | Spinal fixation system |
US5509428A (en) | 1994-05-31 | 1996-04-23 | Dunlop; Richard W. | Method and apparatus for the creation of tricuspid regurgitation |
US5554185A (en) | 1994-07-18 | 1996-09-10 | Block; Peter C. | Inflatable prosthetic cardiovascular valve for percutaneous transluminal implantation of same |
US6217610B1 (en) | 1994-07-29 | 2001-04-17 | Edwards Lifesciences Corporation | Expandable annuloplasty ring |
US5582607A (en) | 1994-09-09 | 1996-12-10 | Carbomedics, Inc. | Heart valve prosthesis rotator with bendable shaft and drive mechanism |
US5814062A (en) | 1994-12-22 | 1998-09-29 | Target Therapeutics, Inc. | Implant delivery assembly with expandable coupling/decoupling mechanism |
US5634936A (en) * | 1995-02-06 | 1997-06-03 | Scimed Life Systems, Inc. | Device for closing a septal defect |
AU6029696A (en) | 1995-06-07 | 1996-12-30 | St. Jude Medical Inc. | Adjustable sizing apparatus for heart annulus |
WO1997001368A1 (en) | 1995-06-26 | 1997-01-16 | Trimedyne, Inc. | Therapeutic appliance releasing device |
US5653712A (en) | 1995-10-02 | 1997-08-05 | Stern; Howard G. | Intramedullary bone groover |
US5649949A (en) | 1996-03-14 | 1997-07-22 | Target Therapeutics, Inc. | Variable cross-section conical vasoocclusive coils |
US5993474A (en) | 1996-06-11 | 1999-11-30 | Asahi Kogaku Kogyo Kabushiki Kaisha | Treatment accessory for endoscope |
US5792179A (en) | 1996-07-16 | 1998-08-11 | Sideris; Eleftherios B. | Retrievable cardiac balloon placement |
US5776075A (en) | 1996-08-09 | 1998-07-07 | Symbiosis Corporation | Endoscopic bioptome jaw assembly having three or more jaws and an endoscopic instrument incorporating same |
US5895391A (en) | 1996-09-27 | 1999-04-20 | Target Therapeutics, Inc. | Ball lock joint and introducer for vaso-occlusive member |
EP0850607A1 (en) | 1996-12-31 | 1998-07-01 | Cordis Corporation | Valve prosthesis for implantation in body channels |
US6406420B1 (en) | 1997-01-02 | 2002-06-18 | Myocor, Inc. | Methods and devices for improving cardiac function in hearts |
US5928224A (en) | 1997-01-24 | 1999-07-27 | Hearten Medical, Inc. | Device for the treatment of damaged heart valve leaflets and methods of using the device |
US6508825B1 (en) | 1997-02-28 | 2003-01-21 | Lumend, Inc. | Apparatus for treating vascular occlusions |
US6090096A (en) | 1997-04-23 | 2000-07-18 | Heartport, Inc. | Antegrade cardioplegia catheter and method |
US5957949A (en) | 1997-05-01 | 1999-09-28 | World Medical Manufacturing Corp. | Percutaneous placement valve stent |
AU9225598A (en) | 1997-09-04 | 1999-03-22 | Endocore, Inc. | Artificial chordae replacement |
US5957865A (en) | 1997-09-25 | 1999-09-28 | Merit Medical Systems, Inc. | Flexible catheter guidewire |
US6332893B1 (en) | 1997-12-17 | 2001-12-25 | Myocor, Inc. | Valve to myocardium tension members device and method |
US6808498B2 (en) * | 1998-02-13 | 2004-10-26 | Ventrica, Inc. | Placing a guide member into a heart chamber through a coronary vessel and delivering devices for placing the coronary vessel in communication with the heart chamber |
US6165183A (en) | 1998-07-15 | 2000-12-26 | St. Jude Medical, Inc. | Mitral and tricuspid valve repair |
US6152144A (en) | 1998-11-06 | 2000-11-28 | Appriva Medical, Inc. | Method and device for left atrial appendage occlusion |
CA2620783C (en) | 1999-04-09 | 2011-04-05 | Evalve, Inc. | Methods and apparatus for cardiac valve repair |
US8216256B2 (en) | 1999-04-09 | 2012-07-10 | Evalve, Inc. | Detachment mechanism for implantable fixation devices |
US6283995B1 (en) | 1999-04-15 | 2001-09-04 | Sulzer Carbomedics Inc. | Heart valve leaflet with scalloped free margin |
US6287339B1 (en) | 1999-05-27 | 2001-09-11 | Sulzer Carbomedics Inc. | Sutureless heart valve prosthesis |
DE69922640D1 (en) | 1999-07-19 | 2005-01-20 | Silvano Uimberto Tramonte Mail | Endosseous dental implant |
US8257428B2 (en) | 1999-08-09 | 2012-09-04 | Cardiokinetix, Inc. | System for improving cardiac function |
US6994092B2 (en) | 1999-11-08 | 2006-02-07 | Ev3 Sunnyvale, Inc. | Device for containing embolic material in the LAA having a plurality of tissue retention structures |
US8579966B2 (en) | 1999-11-17 | 2013-11-12 | Medtronic Corevalve Llc | Prosthetic valve for transluminal delivery |
US7018406B2 (en) | 1999-11-17 | 2006-03-28 | Corevalve Sa | Prosthetic valve for transluminal delivery |
FR2800984B1 (en) | 1999-11-17 | 2001-12-14 | Jacques Seguin | DEVICE FOR REPLACING A HEART VALVE PERCUTANEOUSLY |
US6458153B1 (en) * | 1999-12-31 | 2002-10-01 | Abps Venture One, Ltd. | Endoluminal cardiac and venous valve prostheses and methods of manufacture and delivery thereof |
US6929633B2 (en) | 2000-01-25 | 2005-08-16 | Bacchus Vascular, Inc. | Apparatus and methods for clot dissolution |
NZ520462A (en) | 2000-01-27 | 2004-08-27 | 3F Therapeutics Inc | Prosthetic heart valve |
US6821297B2 (en) | 2000-02-02 | 2004-11-23 | Robert V. Snyders | Artificial heart valve, implantation instrument and method therefor |
US20050070999A1 (en) | 2000-02-02 | 2005-03-31 | Spence Paul A. | Heart valve repair apparatus and methods |
US6797002B2 (en) | 2000-02-02 | 2004-09-28 | Paul A. Spence | Heart valve repair apparatus and methods |
US6478776B1 (en) | 2000-04-05 | 2002-11-12 | Biocardia, Inc. | Implant delivery catheter system and methods for its use |
US6454799B1 (en) | 2000-04-06 | 2002-09-24 | Edwards Lifesciences Corporation | Minimally-invasive heart valves and methods of use |
US7056294B2 (en) | 2000-04-13 | 2006-06-06 | Ev3 Sunnyvale, Inc | Method and apparatus for accessing the left atrial appendage |
US6869444B2 (en) | 2000-05-22 | 2005-03-22 | Shlomo Gabbay | Low invasive implantable cardiac prosthesis and method for helping improve operation of a heart valve |
US6419695B1 (en) | 2000-05-22 | 2002-07-16 | Shlomo Gabbay | Cardiac prosthesis for helping improve operation of a heart valve |
US6440132B1 (en) | 2000-05-24 | 2002-08-27 | Roger P. Jackson | Open head bone screw closure with threaded boss |
US6805711B2 (en) | 2000-06-02 | 2004-10-19 | 3F Therapeutics, Inc. | Expandable medical implant and percutaneous delivery |
US6358277B1 (en) | 2000-06-21 | 2002-03-19 | The International Heart Institute Of Montana Foundation | Atrio-ventricular valvular device |
AU2001271667A1 (en) | 2000-06-30 | 2002-01-14 | Viacor Incorporated | Method and apparatus for performing a procedure on a cardiac valve |
DE20013905U1 (en) | 2000-08-12 | 2000-12-21 | Stryker Trauma Gmbh | Sleeve-shaped device for holding screws when screwing into an object, e.g. into a bone with the help of a screwdriver |
US7510572B2 (en) | 2000-09-12 | 2009-03-31 | Shlomo Gabbay | Implantation system for delivery of a heart valve prosthesis |
US7527646B2 (en) | 2000-09-20 | 2009-05-05 | Ample Medical, Inc. | Devices, systems, and methods for retaining a native heart valve leaflet |
US20050222489A1 (en) | 2003-10-01 | 2005-10-06 | Ample Medical, Inc. | Devices, systems, and methods for reshaping a heart valve annulus, including the use of a bridge implant |
US6461382B1 (en) | 2000-09-22 | 2002-10-08 | Edwards Lifesciences Corporation | Flexible heart valve having moveable commissures |
US7070618B2 (en) | 2000-10-25 | 2006-07-04 | Viacor, Inc. | Mitral shield |
US6482228B1 (en) | 2000-11-14 | 2002-11-19 | Troy R. Norred | Percutaneous aortic valve replacement |
US6974476B2 (en) | 2003-05-05 | 2005-12-13 | Rex Medical, L.P. | Percutaneous aortic valve |
US6746404B2 (en) | 2000-12-18 | 2004-06-08 | Biosense, Inc. | Method for anchoring a medical device between tissue |
US6454798B1 (en) | 2000-12-21 | 2002-09-24 | Sulzer Carbomedics Inc. | Polymer heart valve with helical coaption surface |
AU2002250207B2 (en) | 2001-03-05 | 2006-07-27 | Covidien Lp | Surgical grasping instrument |
US7186264B2 (en) | 2001-03-29 | 2007-03-06 | Viacor, Inc. | Method and apparatus for improving mitral valve function |
US20020188170A1 (en) | 2001-04-27 | 2002-12-12 | Santamore William P. | Prevention of myocardial infarction induced ventricular expansion and remodeling |
US6673100B2 (en) | 2001-05-25 | 2004-01-06 | Cordis Neurovascular, Inc. | Method and device for retrieving embolic coils |
US6592606B2 (en) | 2001-08-31 | 2003-07-15 | Advanced Cardiovascular Systems, Inc. | Hinged short cage for an embolic protection device |
GB0125925D0 (en) | 2001-10-29 | 2001-12-19 | Univ Glasgow | Mitral valve prosthesis |
US6824562B2 (en) | 2002-05-08 | 2004-11-30 | Cardiac Dimensions, Inc. | Body lumen device anchor, device and assembly |
US6978176B2 (en) | 2001-12-08 | 2005-12-20 | Lattouf Omar M | Treatment for patient with congestive heart failure |
US20030144573A1 (en) | 2001-12-19 | 2003-07-31 | Heilman Marlin S. | Back-flow limiting valve member |
US20030144574A1 (en) | 2001-12-19 | 2003-07-31 | Heilman Marlin S. | Method and apparatus for providing limited back-flow in a blood pump during a non-pumping state |
US6764510B2 (en) | 2002-01-09 | 2004-07-20 | Myocor, Inc. | Devices and methods for heart valve treatment |
JP4465192B2 (en) | 2002-03-15 | 2010-05-19 | エヌエムティー メディカル, インコーポレイティッド | A binding system useful in implant placement |
US7572276B2 (en) | 2002-05-06 | 2009-08-11 | Warsaw Orthopedic, Inc. | Minimally invasive instruments and methods for inserting implants |
US7101395B2 (en) | 2002-06-12 | 2006-09-05 | Mitral Interventions, Inc. | Method and apparatus for tissue connection |
EP1581144A4 (en) | 2002-06-27 | 2007-07-11 | Gen Hospital Corp | Systems for and methods of atrioventricular valve regurgitation and reversing ventricular remodeling |
US8348963B2 (en) | 2002-07-03 | 2013-01-08 | Hlt, Inc. | Leaflet reinforcement for regurgitant valves |
KR100442330B1 (en) | 2002-09-03 | 2004-07-30 | 주식회사 엠아이텍 | Stent and manufacturing method the same |
DE60322567D1 (en) | 2002-10-10 | 2008-09-11 | Cleveland Clinic Foundation | DEVICE FOR REPLACING A MITRAL FLAP WITH A STAINLESS BIOPROTHETIC FLAP WITH CHORDAE |
US7112219B2 (en) | 2002-11-12 | 2006-09-26 | Myocor, Inc. | Devices and methods for heart valve treatment |
US7247134B2 (en) | 2002-11-12 | 2007-07-24 | Myocor, Inc. | Devices and methods for heart valve treatment |
US7404824B1 (en) | 2002-11-15 | 2008-07-29 | Advanced Cardiovascular Systems, Inc. | Valve aptation assist device |
US6830585B1 (en) | 2003-01-14 | 2004-12-14 | 3F Therapeutics, Inc. | Percutaneously deliverable heart valve and methods of implantation |
US7381210B2 (en) | 2003-03-14 | 2008-06-03 | Edwards Lifesciences Corporation | Mitral valve repair system and method for use |
US7473266B2 (en) | 2003-03-14 | 2009-01-06 | Nmt Medical, Inc. | Collet-based delivery system |
US7175656B2 (en) | 2003-04-18 | 2007-02-13 | Alexander Khairkhahan | Percutaneous transcatheter heart valve replacement |
EP1472996B1 (en) | 2003-04-30 | 2009-09-30 | Medtronic Vascular, Inc. | Percutaneously delivered temporary valve |
TW590007U (en) | 2003-06-06 | 2004-06-01 | Univ Tamkang | Tri-leaflet mechanical heart valve |
US7537592B2 (en) | 2003-06-20 | 2009-05-26 | Plc Medical Systems, Inc. | Endovascular tissue removal device |
US7204255B2 (en) | 2003-07-28 | 2007-04-17 | Plc Medical Systems, Inc. | Endovascular tissue removal device |
US7160322B2 (en) | 2003-08-13 | 2007-01-09 | Shlomo Gabbay | Implantable cardiac prosthesis for mitigating prolapse of a heart valve |
US20050038509A1 (en) | 2003-08-14 | 2005-02-17 | Ashe Kassem Ali | Valve prosthesis including a prosthetic leaflet |
WO2005039392A2 (en) | 2003-10-22 | 2005-05-06 | Endius Incorporated | Method and surgical tool for inserting a longitudinal member |
US7056286B2 (en) | 2003-11-12 | 2006-06-06 | Adrian Ravenscroft | Medical device anchor and delivery system |
US20050159810A1 (en) | 2004-01-15 | 2005-07-21 | Farzan Filsoufi | Devices and methods for repairing cardiac valves |
US8377118B2 (en) * | 2004-05-05 | 2013-02-19 | Direct Flow Medical, Inc. | Unstented heart valve with formed in place support structure |
US7704268B2 (en) | 2004-05-07 | 2010-04-27 | Nmt Medical, Inc. | Closure device with hinges |
US7704277B2 (en) | 2004-09-14 | 2010-04-27 | Edwards Lifesciences Ag | Device and method for treatment of heart valve regurgitation |
US7658757B2 (en) | 2004-10-08 | 2010-02-09 | Boston Scientific Scimed, Inc. | Endoprosthesis delivery system |
WO2006064490A1 (en) | 2004-12-15 | 2006-06-22 | Mednua Limited | A medical device suitable for use in treatment of a valve |
WO2009053952A2 (en) | 2007-10-26 | 2009-04-30 | Mednua Limited | A medical device for use in treatment of a valve |
EP3967269A3 (en) | 2005-02-07 | 2022-07-13 | Evalve, Inc. | Systems and devices for cardiac valve repair |
WO2006091597A1 (en) | 2005-02-22 | 2006-08-31 | Cardiofocus, Inc. | Deflectable sheath catheters |
US8083793B2 (en) | 2005-02-28 | 2011-12-27 | Medtronic, Inc. | Two piece heart valves including multiple lobe valves and methods for implanting them |
US20060199995A1 (en) | 2005-03-02 | 2006-09-07 | Venkataramana Vijay | Percutaneous cardiac ventricular geometry restoration device and treatment for heart failure |
SE531468C2 (en) | 2005-04-21 | 2009-04-14 | Edwards Lifesciences Ag | An apparatus for controlling blood flow |
US8002742B2 (en) | 2005-04-22 | 2011-08-23 | Accessclosure, Inc. | Apparatus and methods for sealing a puncture in tissue |
WO2006127509A2 (en) | 2005-05-20 | 2006-11-30 | Mayo Foundation For Medical Education And Research | Devices and methods for reducing cardiac valve regurgitation |
US20060293698A1 (en) | 2005-06-28 | 2006-12-28 | Medtronic Vascular, Inc. | Retainer device for mitral valve leaflets |
WO2007012046A2 (en) | 2005-07-19 | 2007-01-25 | Stout Medical Group, L.P. | Anatomical measurement tool |
US20070049980A1 (en) | 2005-08-30 | 2007-03-01 | Zielinski Todd M | Trans-septal pressure sensor |
US8852270B2 (en) | 2007-11-15 | 2014-10-07 | Cardiosolutions, Inc. | Implant delivery system and method |
US8216302B2 (en) | 2005-10-26 | 2012-07-10 | Cardiosolutions, Inc. | Implant delivery and deployment system and method |
US8449606B2 (en) | 2005-10-26 | 2013-05-28 | Cardiosolutions, Inc. | Balloon mitral spacer |
US8778017B2 (en) | 2005-10-26 | 2014-07-15 | Cardiosolutions, Inc. | Safety for mitral valve implant |
US9259317B2 (en) | 2008-06-13 | 2016-02-16 | Cardiosolutions, Inc. | System and method for implanting a heart implant |
US8092525B2 (en) | 2005-10-26 | 2012-01-10 | Cardiosolutions, Inc. | Heart valve implant |
US7785366B2 (en) | 2005-10-26 | 2010-08-31 | Maurer Christopher W | Mitral spacer |
WO2007059018A2 (en) | 2005-11-10 | 2007-05-24 | Phase One Medical Llc | Catheter device |
US20070118151A1 (en) | 2005-11-21 | 2007-05-24 | The Brigham And Women's Hospital, Inc. | Percutaneous cardiac valve repair with adjustable artificial chordae |
US20080221566A1 (en) | 2005-11-29 | 2008-09-11 | Krishnan Subramaniam C | Method and apparatus for detecting and achieving closure of patent foramen ovale |
US8142470B2 (en) | 2005-12-01 | 2012-03-27 | Atritech, Inc. | Method for accessing the left atrial appendage with a balloon-tipped transeptal sheath |
WO2007078772A1 (en) | 2005-12-15 | 2007-07-12 | The Cleveland Clinic Foundation | Apparatus and method for treating a regurgitant valve |
CA2669195C (en) | 2005-12-15 | 2013-06-25 | Georgia Tech Research Corporation | Systems and methods to control the dimension of a heart valve |
WO2007073566A1 (en) | 2005-12-22 | 2007-06-28 | Nmt Medical, Inc. | Catch members for occluder devices |
US20070185571A1 (en) | 2006-02-06 | 2007-08-09 | The Cleveland Clinic Foundation | Apparatus and method for treating a regurgitant valve |
US20070198050A1 (en) | 2006-02-22 | 2007-08-23 | Phase One Medica, Llc | Medical implant device |
US7536228B2 (en) | 2006-03-24 | 2009-05-19 | Micardia Corporation | Activation device for dynamic ring manipulation |
EP3241525B2 (en) | 2006-06-01 | 2022-06-08 | Edwards Lifesciences Corporation | Prosthetic insert for use with a mitral valve |
WO2007144865A1 (en) | 2006-06-15 | 2007-12-21 | Mednua Limited | A medical device suitable for use in treatment of a valve |
US7657326B2 (en) | 2006-11-08 | 2010-02-02 | Cardiac Pacemakers, Inc. | Cardiac lead with a retractable helix |
US8337518B2 (en) | 2006-12-20 | 2012-12-25 | Onset Medical Corporation | Expandable trans-septal sheath |
US20080208328A1 (en) | 2007-02-23 | 2008-08-28 | Endovalve, Inc. | Systems and Methods For Placement of Valve Prosthesis System |
US8480730B2 (en) | 2007-05-14 | 2013-07-09 | Cardiosolutions, Inc. | Solid construct mitral spacer |
US20090105815A1 (en) | 2007-10-19 | 2009-04-23 | Matthew Krever | Push-in retainer system for use in the direct plication annuloplasty treatment of mitral valve regurgitation |
US8597347B2 (en) | 2007-11-15 | 2013-12-03 | Cardiosolutions, Inc. | Heart regurgitation method and apparatus |
US8591460B2 (en) | 2008-06-13 | 2013-11-26 | Cardiosolutions, Inc. | Steerable catheter and dilator and system and method for implanting a heart implant |
-
2007
- 2007-05-14 US US11/748,121 patent/US8449606B2/en active Active
-
2008
- 2008-05-14 BR BRPI0810270A patent/BRPI0810270A2/en not_active IP Right Cessation
- 2008-05-14 EP EP08755418.4A patent/EP2150206B1/en active Active
- 2008-05-14 WO PCT/US2008/063560 patent/WO2008141322A1/en active Application Filing
- 2008-05-14 CA CA2697358A patent/CA2697358C/en active Active
-
2013
- 2013-04-23 US US13/868,399 patent/US8894705B2/en active Active
-
2014
- 2014-11-14 US US14/541,270 patent/US20150073547A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP2150206A4 (en) | 2010-12-29 |
WO2008141322A1 (en) | 2008-11-20 |
US8894705B2 (en) | 2014-11-25 |
US20130310925A1 (en) | 2013-11-21 |
EP2150206B1 (en) | 2013-08-14 |
US20070255399A1 (en) | 2007-11-01 |
US8449606B2 (en) | 2013-05-28 |
CA2697358C (en) | 2016-04-05 |
BRPI0810270A2 (en) | 2016-07-19 |
EP2150206A1 (en) | 2010-02-10 |
US20150073547A1 (en) | 2015-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8894705B2 (en) | Balloon mitral spacer | |
US8888844B2 (en) | Heart valve implant | |
US9232999B2 (en) | Mitral spacer | |
US8480730B2 (en) | Solid construct mitral spacer | |
JP6546906B2 (en) | Transapical implant systems, implants and methods | |
EP2982337B1 (en) | Paravalvular leak detection, sealing, and prevention | |
JP6605445B2 (en) | Mitral valve spacer or system and method for implanting it | |
US20170325949A1 (en) | Heart Valve Implant And Methods For Delivering And Implanting Same | |
US9119715B2 (en) | Collapsible/expandable prosthetic heart valve delivery system and methods | |
JP6018064B2 (en) | System and method for rapid placement of a surgical heart valve | |
US20070265700A1 (en) | Safety for Mitral Valve Plug | |
US20040127979A1 (en) | Method of treating diseased valve |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20130514 |